<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Viruses</journal-id><journal-id journal-id-type="iso-abbrev">Viruses</journal-id><journal-id journal-id-type="publisher-id">viruses</journal-id><journal-title-group><journal-title>Viruses</journal-title></journal-title-group><issn pub-type="epub">1999-4915</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11680368</article-id><article-id pub-id-type="doi">10.3390/v16121944</article-id><article-id pub-id-type="publisher-id">viruses-16-01944</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Human Melanoma and Glioblastoma Cells Express Cathepsins Supporting Reovirus Moscow Strain Infection</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-0223-5738</contrib-id><name><surname>Ammour</surname><given-names>Yulia</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><xref rid="af1-viruses-16-01944" ref-type="aff">1</xref><xref rid="af2-viruses-16-01944" ref-type="aff">2</xref><xref rid="c1-viruses-16-01944" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-2898-9722</contrib-id><name><surname>Nikolaeva</surname><given-names>Eugenia</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><xref rid="af1-viruses-16-01944" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0003-2645-4799</contrib-id><name><surname>Sagimbaeva</surname><given-names>Olesya</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><xref rid="af1-viruses-16-01944" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Shamsutdinov</surname><given-names>Pavel</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><xref rid="af1-viruses-16-01944" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Astapenko</surname><given-names>Anastasia</given-names></name><xref rid="af1-viruses-16-01944" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Zhelaeva</surname><given-names>Yulia</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><xref rid="af1-viruses-16-01944" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Gavrilova</surname><given-names>Marina</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><xref rid="af1-viruses-16-01944" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Susova</surname><given-names>Olga</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><xref rid="af3-viruses-16-01944" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Mitrofanov</surname><given-names>Aleksey</given-names></name><xref rid="af3-viruses-16-01944" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-4160-9598</contrib-id><name><surname>Bekyashev</surname><given-names>Ali</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><xref rid="af3-viruses-16-01944" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-2642-4202</contrib-id><name><surname>Nasedkina</surname><given-names>Tatiana</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><xref rid="af2-viruses-16-01944" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Svitich</surname><given-names>Oxana</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><xref rid="af1-viruses-16-01944" ref-type="aff">1</xref><xref rid="af4-viruses-16-01944" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name><surname>Faizuloev</surname><given-names>Evgeny</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af1-viruses-16-01944" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Zverev</surname><given-names>Vitaly</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="af1-viruses-16-01944" ref-type="aff">1</xref><xref rid="af4-viruses-16-01944" ref-type="aff">4</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Calistri</surname><given-names>Arianna</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name><surname>Tuyaerts</surname><given-names>Sandra</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-viruses-16-01944"><label>1</label>I.I. Mechnikov Research Institute for Vaccines and Sera, 105064 Moscow, Russia; <email>jane.niko.biochem@gmail.com</email> (E.N.); <email>olisiya.s@gmail.com</email> (O.S.); <email>977876@mail.ru</email> (P.S.); <email>ekzis666@mail.ru</email> (A.A.); <email>yushchetinina@gmail.com</email> (Y.Z.); <email>gavrilovamv@gmail.com</email> (M.G.); <email>svitichoa@yandex.ru</email> (O.S.); <email>faizuloev@mail.ru</email> (E.F.); <email>vitalyzverev@outlook.com</email> (V.Z.)</aff><aff id="af2-viruses-16-01944"><label>2</label>Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 Moscow, Russia; <email>tanased06@rambler.ru</email></aff><aff id="af3-viruses-16-01944"><label>3</label>N.N. Blokhin Russian Cancer Research Center of the Ministry of Health of the Russian Federation, 115478 Moscow, Russia; <email>susovaolga@gmail.com</email> (O.S.); <email>mitrofanov-aa@list.ru</email> (A.M.); <email>abekyashev@gmail.com</email> (A.B.)</aff><aff id="af4-viruses-16-01944"><label>4</label>I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation, 119146 Moscow, Russia</aff><author-notes><corresp id="c1-viruses-16-01944"><label>*</label>Correspondence: <email>yulia.ammour@yahoo.fr</email>; Tel.: +7-495-674-7798</corresp></author-notes><pub-date pub-type="epub"><day>19</day><month>12</month><year>2024</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2024</year></pub-date><volume>16</volume><issue>12</issue><elocation-id>1944</elocation-id><history><date date-type="received"><day>05</day><month>11</month><year>2024</year></date><date date-type="rev-recd"><day>16</day><month>12</month><year>2024</year></date><date date-type="accepted"><day>17</day><month>12</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; 2024 by the authors.</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>This study evaluates the oncolytic potential of the Moscow strain of reovirus against human metastatic melanoma and glioblastoma cells. The Moscow strain effectively infects and replicates within human melanoma cell lines and primary glioblastoma cells, while sparing non-malignant human cells. Infection leads to the selective destruction of neoplastic cells, mediated by functional viral replication. A positive correlation was identified between viral RNA accumulation and tumor cell death, with no replication observed in non-malignant cells. This study highlights the critical roles of cathepsins B, L, and S as mediators of the oncolytic process. The pharmacological inhibition of these enzymes significantly attenuated reovirus-induced cytotoxicity in melanoma and glioblastoma cells. Conversely, PKR production analysis revealed minimal activation in reovirus-infected tumor cells, suggesting that the hyperactivation of the RAS-signaling pathway and subsequent PKR inhibition do not directly contribute to the selective efficacy of reovirus. Moreover, infected tumor cells exhibited features of both apoptotic and non-apoptotic death, emphasizing the intricate mechanisms of reovirus-mediated oncolysis. These findings underscore the therapeutic promise of the Moscow strain of reovirus as a selective and potent oncolytic agent for targeting melanoma and glioblastoma cells.</p></abstract><kwd-group><kwd>oncolytic viruses</kwd><kwd>reovirus</kwd><kwd>cathepsins</kwd><kwd>glioblastoma</kwd><kwd>melanoma</kwd></kwd-group><funding-group><award-group><funding-source>Ministry of Science and Higher Education of the Russian Federation</funding-source><award-id>FGFS-2022-0005</award-id></award-group><award-group><funding-source>Russian Science Foundation</funding-source><award-id>22-15-00304</award-id></award-group><funding-statement><named-content content-type="citation"><xref rid="sec3dot1-viruses-16-01944" ref-type="sec">Section 3.1</xref></named-content>, <named-content content-type="citation"><xref rid="sec3dot3-viruses-16-01944" ref-type="sec">Section 3.3</xref></named-content> and <named-content content-type="citation"><xref rid="sec3dot5-viruses-16-01944" ref-type="sec">Section 3.5</xref></named-content> of this study were carried out with the financial support of the Ministry of Science and Higher Education of the Russian Federation (Theme no. FGFS-2022-0005) using scientific equipment of the Collective Use Center &#x0201c;I. I. Mechnikov NIIVS&#x0201d;, Moscow, Russia (Agreement No. 075-11-2021-676 dated 28 July 2021). <named-content content-type="citation"><xref rid="sec3dot2-viruses-16-01944" ref-type="sec">Section 3.2</xref></named-content> and <named-content content-type="citation"><xref rid="sec3dot4-viruses-16-01944" ref-type="sec">Section 3.4</xref></named-content> of this study were financially supported by the Russian Science Foundation (project no. 22-15-00304).</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-viruses-16-01944"><title>1. Introduction</title><p>Malignant neoplasms represent a significant and escalating challenge to modern healthcare systems. In Russia alone, cancer accounts for nearly 300,000 deaths annually, with approximately 600,000 new cases diagnosed each year [<xref rid="B1-viruses-16-01944" ref-type="bibr">1</xref>]. Among the most aggressive and metastatic cancers, human melanoma and glioblastoma exhibit rising global incidence rates, outpacing the growth of other cancer types and imposing a significant socioeconomic burden. While early-stage melanoma can often be effectively treated through surgical intervention, recurrence remains a pressing concern. Notably, approximately 10% of cases present at an advanced, often inoperable or metastatic stage. The five-year survival rate for patients with metastatic melanoma has improved substantially, increasing from less than 10% to 40&#x02013;50%, owing to advancements in immunotherapy and targeted therapies [<xref rid="B2-viruses-16-01944" ref-type="bibr">2</xref>]. However, these malignancies remain highly resistant to conventional treatments, including cytostatic chemotherapy, radiation, and hormonal therapy.</p><p>Glioblastomas, characterized by poor prognosis and near-inevitable recurrence, continue to represent a critical therapeutic challenge. Standard treatment protocols encompassing surgical resection, temozolomide-based chemotherapy, and radiotherapy yield a median overall survival of only 14 to 18 months [<xref rid="B3-viruses-16-01944" ref-type="bibr">3</xref>]. The high degree of heterogeneity inherent to glioma and glioblastoma cells further complicates treatment strategies, contributing to the frequent failure of immunotherapy and targeted chemotherapies [<xref rid="B4-viruses-16-01944" ref-type="bibr">4</xref>,<xref rid="B5-viruses-16-01944" ref-type="bibr">5</xref>]. These limitations underscore the urgent need for innovative therapeutic strategies that offer improved efficacy while minimizing toxicity.</p><p>Oncolytic virotherapy has emerged as a promising approach in this context, offering the potential to selectively target tumor cells while sparing healthy tissues. This strategy not only directly destroys tumor cells but also enhances anti-tumor immune responses by activating natural killer and cytotoxic T cells, thereby restoring immune surveillance [<xref rid="B6-viruses-16-01944" ref-type="bibr">6</xref>].</p><p>The concept of oncolytic virotherapy for glioblastoma treatment was pioneered by R.L. Martuza and colleagues, who, in 1991, used herpes simplex virus-1 with attenuated neurovirulence to treat glioblastoma in vivo [<xref rid="B7-viruses-16-01944" ref-type="bibr">7</xref>]. To date, herpes viruses, adenovirus, Newcastle disease virus, myxoma virus, measles virus, poliovirus, parvovirus, and Zika virus have the greatest proven oncolytic efficacy [<xref rid="B8-viruses-16-01944" ref-type="bibr">8</xref>]. Advances in genetic engineering have enabled the development of viruses with enhanced tropism for brain tissue, capable of crossing the blood&#x02013;brain barrier and disrupting critical tumor cell processes, such as metabolism, proliferation, and differentiation. Despite these advancements, identifying the most effective oncolytic virus remains challenging due to the molecular and genetic heterogeneity of glioblastoma.</p><p>Among oncolytic viruses, the mammalian orthoreovirus has garnered attention for its natural tropism toward specific malignancies, including melanoma and glioblastoma [<xref rid="B9-viruses-16-01944" ref-type="bibr">9</xref>]. Notably, reovirus is non-pathogenic to humans, obviating the need for attenuation and making it an attractive therapeutic candidate.</p><p>The oncolytic efficacy of reovirus is intrinsically linked to specific mutations within tumor cells, which influence their growth, survival, and immune evasion [<xref rid="B10-viruses-16-01944" ref-type="bibr">10</xref>,<xref rid="B11-viruses-16-01944" ref-type="bibr">11</xref>,<xref rid="B12-viruses-16-01944" ref-type="bibr">12</xref>]. These mutations predominantly involve the hyperactivation of signaling pathways that facilitate viral replication in tumor cells and the overproduction of proteases crucial for viral disassembly within the cell. These mechanisms collectively enable the efficient dissemination of reovirus within tumor tissues, reinforcing its potential as a targeted oncolytic agent.</p><p>In early studies exploring tumor cells&#x02019; susceptibility to reovirus, the transfection of murine cells with epidermal growth factor receptor (EGFR) significantly enhanced both reovirus replication and virus-induced cytopathic effects [<xref rid="B13-viruses-16-01944" ref-type="bibr">13</xref>]. Initially proposed as a direct receptor for reovirus, EGFR was later found to facilitate viral replication by activating Ras-mediated signaling pathway [<xref rid="B14-viruses-16-01944" ref-type="bibr">14</xref>]. EGFR hyperactivation is a hallmark of numerous human tumors [<xref rid="B15-viruses-16-01944" ref-type="bibr">15</xref>], where it drives Ras signaling to promote tumor proliferation and survival [<xref rid="B16-viruses-16-01944" ref-type="bibr">16</xref>]. In addition, Ras expression has been shown to enhance the sensitivity of mouse fibroblasts to reovirus, further implicating this pathway in the selective vulnerability of tumor cells [<xref rid="B17-viruses-16-01944" ref-type="bibr">17</xref>].</p><p>Clinical trials have demonstrated the safety and therapeutic efficacy of the T3 Dearing (T3D) strain of reovirus, known as Pelareorep or Reolysin, in patients with melanoma (NCT00984464) and glioblastoma (NCT00528684). Approved by the FDA for the treatment of solid tumors and hematologic malignancies, this strain exerts direct cytotoxic effects on cancer cells, while simultaneously activating innate anti-tumor immunity [<xref rid="B18-viruses-16-01944" ref-type="bibr">18</xref>,<xref rid="B19-viruses-16-01944" ref-type="bibr">19</xref>]. Additionally, reovirus infection sensitizes tumor cells to conventional chemotherapeutic agents and radiotherapy, underscoring it as a promising candidate for combination approach treatments [<xref rid="B10-viruses-16-01944" ref-type="bibr">10</xref>]. Ongoing research efforts aim to enhance the efficacy of reovirus-based combination therapies and to evaluate its synergy with immunotherapeutic approaches. Current clinical studies are exploring the integration of reovirus with diverse therapeutic agents to address various human malignancies.</p><p>The present study aimed to assess the oncolytic potential of the Moscow strain of reovirus against human metastatic melanoma cell lines and primary glioblastoma cells. This work examines the responsiveness of tumor cells to reovirus-mediated oncolysis, evaluates the kinetics of viral accumulation and tumor cell death following infection, and elucidates the functional mechanisms underlying the selective oncolytic activity of the Moscow strain. Particular focus is placed on identifying cellular factors that modulate sensitivity or resistance to viral oncolysis.</p><p>Initially, the Moscow strain was isolated from a component of the medium used for rotavirus cultivation in MA-104 cells [<xref rid="B20-viruses-16-01944" ref-type="bibr">20</xref>]. After 5&#x02013;9 passages in the cell line, the rotavirus RNA disappeared as measured by qPCR [<xref rid="B21-viruses-16-01944" ref-type="bibr">21</xref>], while the cells continued to undergo cytopathic changes compared to the control. The SDS-PAGE analysis of the isolated genome RNA revealed the presence of 10 segments in the proportion of 3:3:4 corresponding to the reovirus genome. The consequent sequencing confirmed the reovirus [<xref rid="B20-viruses-16-01944" ref-type="bibr">20</xref>]. Thus, as the Moscow strain of reovirus was isolated in trypsin-containing medium, the virus passaging in the absence of trypsin lead to aborted cytopathic effects, indicating the strong dependence of virus reproduction on the presence of trypsin in the nutrient medium. Thus, the characteristics of the Moscow strain according to its dependence on the proteases were of particular interest in this work.</p></sec><sec id="sec2-viruses-16-01944"><title>2. Materials and Methods</title><sec id="sec2dot1-viruses-16-01944"><title>2.1. Virus and Cells</title><p>The mammalian orthoreovirus Moscow strain (GenBank, N&#x000b0; MH170361) isolated at the I.I. Mechnikov Research Institute for Vaccines and Sera was used in this work [<xref rid="B20-viruses-16-01944" ref-type="bibr">20</xref>]. Reovirus with an average titer of 7.48 log<sub>10</sub> PFU/mL was cultured and titrated in MA-104 cells, and then serially diluted, aliquoted, and stored at &#x02212;70 &#x000b0;C. MA-104 cells and human lung carcinoma cells, A549, were obtained from the collection of the I.I. Mechnikov Research Institute for Vaccines and Sera.</p><p>Differentiated human metastatic melanoma cell lines Mel Ibr (&#x0003e;100 passages) and Mel Z (31 passages) and poorly differentiated cell lines Mel Il (&#x0003e;100 passages) and Mel Mtp (39 passages) (<xref rid="app1-viruses-16-01944" ref-type="app">Supplementary Table S1</xref>), as well as immortalized human hTERT-BJ fibroblasts and normal kidney epithelial (NKE) cells, were obtained from the collection of the N.N. Blokhin Research Center (Moscow, Russia).</p><p>Glioblastoma multiform (GBM) cells Gbl13n, Gbl16n, Gbl17n, Gbl24n, Gbl25n, and Gbl27n at early passages (6&#x02013;10 passages) were established from primary tumor cells at the N.N. Blokhin Russian Cancer Research Center from the surgical resection or biopsies of confirmed GBM cases and genetically characterized. All patients gave their informed consent. The molecular&#x02013;genetic profile of cell lines was performed using NGS sequencing. The mutations found are summarized in [<xref rid="B22-viruses-16-01944" ref-type="bibr">22</xref>,<xref rid="B23-viruses-16-01944" ref-type="bibr">23</xref>].</p><p>Melanoma and glioblastoma cells were cultured as described in previous works [<xref rid="B21-viruses-16-01944" ref-type="bibr">21</xref>,<xref rid="B23-viruses-16-01944" ref-type="bibr">23</xref>].</p></sec><sec id="sec2dot2-viruses-16-01944"><title>2.2. Infection of Cell Lines with Reovirus</title><p>When a cell monolayer reached 80&#x02013;90% confluency in T25 flasks (Corning, Oneonta, NY, USA), it was rinsed with 3 mL of Hanks&#x02019; Balanced Salt Solution (HBSS, Servicebio Technology Co., Wuhan, Hubei, China) solution. Considering the cell count per vial and the initial viral titer, a range of virus dilutions was prepared in DMEM/F12 (Servicebio) supplemented with HEPES (PanEco, Gorki Leninskie, Russia), 1% (<italic toggle="yes">v</italic>/<italic toggle="yes">v</italic>) GlutaMAX (Life Technologies, Paisley, UK), and 1% (<italic toggle="yes">v</italic>/<italic toggle="yes">v</italic>) Pen/Strep (Life Technologies). Subsequently, 2 mL of these dilutions was added to each cell line at varying multiplicities of infection (MOIs). The infected cells were then incubated at a controlled temperature of 37 &#x000b1; 1 &#x000b0;C in an environment with 5% CO<sub>2</sub> for 2 h. Control groups included uninfected cells, cells treated with reovirus inactivated by heating at 56 &#x000b0;C for 30 min, and reovirus deactivated by UV irradiation (20,000 &#x003bc;J/cm<sup>2</sup> for 1 h). Following the viral adsorption phase, the inoculum was discarded, and the cells were washed with HBSS and cultured in growth medium supplemented with 2% fetal bovine serum (FBS; HyClone, South Logan, UT, USA) at 37 &#x000b1; 1 &#x000b0;C in a 5% CO<sub>2</sub> atmosphere for 5 days.</p><p>Infected cells were collected daily to determine the kinetics of viral accumulation. Flasks were subjected to multiple freeze&#x02013;thaw cycles (2&#x02013;3 times) and clarified through low-speed centrifugation at 3000 rpm for 10 min using an LMC-3000 centrifuge (Biosan, Riga, Latvia). Virus titration was performed using 40 L of the viral-containing sample in 96-well plates (Corning, Kennebunk, ME, USA) at 37 &#x000b1; 1 &#x000b0;C in a 5% CO<sub>2</sub>. Each sample was inoculated with three replicate wells. At 24 hours post infection, 10 &#x003bc;L of a 4.5% Triton (Sigma, Kawasaki, Japan) solution was added to each well. The plates were covered with a foil seal and placed at &#x02212;70 &#x000b0;C prior to qPCR analysis.</p><p>In parallel, the cell monolayer from a duplicate flask was lysed in 300 &#x003bc;L of RLT lysis buffer (Qiagen, Hilden, Germany) per well, at specific time points: 0, 24, 48, 72, and 96 hours post infection (h.p.i.). The cell lysates were then centrifuged at 1000 rpm for 5 min, and the resultant supernatants were preserved at &#x02212;70 &#x000b0;C until further examination.</p></sec><sec id="sec2dot3-viruses-16-01944"><title>2.3. Assessment of Cell Survival by MTT Assay</title><p>A total of 100 &#x003bc;L of growth medium containing 1.5 &#x000d7; 10<sup>4</sup> cells was seeded into each well of 96-well plates. Cells were infected with serial dilutions of virus-containing material, as described above, and incubated at 37 &#x000b0;C in a 5% CO<sub>2</sub> atmosphere for 3&#x02013;120 h.p.i. Every 24 h, 25 &#x003bc;L of a solution of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazol bromide (MTT, Promega, Madison, WI, USA) was added as described previously [<xref rid="B24-viruses-16-01944" ref-type="bibr">24</xref>]. Optical density analysis was performed on an Anthos Zenith 3100 microplate detector (Anthos Labtec Instruments, Salzburg, Austria) at a wavelength of 570/650 nm.</p><p>A total of 100 &#x003bc;L of growth medium containing 1.5 &#x000d7; 10<sup>4</sup> tumor cells was added to the wells of 96-well plates. After 24&#x02013;48 h, cells were incubated with a solution of cathepsin B and L inhibitor (Cathepsin Inhibitor I, Calbiochem, EMD Millipore Corp., Billerica, MA, USA) or a pan-inhibitor (Protease inhibitor Cocktail, Sigma-Aldrich, Steinheim, Germany) at a concentration of 5 or 10 &#x003bc;g/mL per well for 1 hour at 37 &#x000b0;C in a 5% CO<sub>2</sub> atmosphere. Then, the cells were infected with serial dilutions of virus-containing material, and the same manipulations described previously were performed.</p></sec><sec id="sec2dot4-viruses-16-01944"><title>2.4. Quantitative Reverse Transcription and Real-Time PCR-Based (qPCR) Potency Assay</title><p>The triton-lysed infection plates were mixed on a Plate Vortexer for 10 s and centrifuged at 1000 rpm for 1 min. Virus replication was assessed by the viral RNA level using the qPCR method. A commercial One-Step RT-PCR kit (OT-2, Syntol, Moscow, Russia) was used to perform the qPCR according to the kit manufacturer&#x02019;s recommendations. The forward (CAGCGCGCGCTATTACGATTAC) and reverse (CTGAAGTCCCACCATCAATAAC) primers and fluorescence-labeled probe (ROX-TGCTTTCTTATCAGCGCCCAATGTC-BHQ2) for the qPCR were synthesized at Syntol (Russia). qPCR was performed in a final volume of 25 &#x003bc;L containing 10&#x02013;50 ng of RNA matrix, a mixture of the forward and reverse primers, and the TaqMan probe with a concentration of 10 &#x003bc;mol, a reaction mixture including buffer solution, 0.5 mM of dNTP, 2.5 mM of MgCl<sub>2</sub>, Hot Start Taq polymerase, reverse transcriptase, and 20 units of RNase inhibitor in two replicates. qPCR was performed on a DTprime5 instrument (DNA Technology, Moscow, Russia). The cycling conditions were as follows: stage 1: 45 &#x000b0;C for 10 min; stage 2: 98 &#x000b0;C for 2 min; and stage 3: 40 cycles&#x02014;98 &#x000b0;C for 10 s, 55 &#x000b0;C for 10 s, and 72 &#x000b0;C for 30 s. Data analysis was performed according to [<xref rid="B25-viruses-16-01944" ref-type="bibr">25</xref>].</p></sec><sec id="sec2dot5-viruses-16-01944"><title>2.5. Total mRNA Isolation and Reverse Transcription Real-Time Quantitative PCR (RT&#x02013;qPCR)</title><p>Total RNA was isolated from cell lysates using a commercial RNeasy Mini Kit (Qiagen) according to the manufacturer&#x02019;s instructions. Purified RNA was eluted from the RNeasy Mini Spin column membrane twice with 50 &#x003bc;L of RNase-free water, and the RNA concentration was estimated on a NanoDrop 8000 (Thermo Fisher Scientific, Wilmington, DE, USA) instrument. DNA impurity was removed by treatment with DNAase 20 U (Syntol) for 30 min.</p><p>To determine the expression level of target genes, 1 &#x003bc;g of total RNA was incubated at 42 &#x000b0;C for 1 h with the following components (Syntol): 1 unit of reverse transcriptase, 5 &#x003bc;M random hexamers or oligo(dT) primer, 5-fold buffer solution (250 mM Tris-HCl (pH 8.3), 250 mM KCl, 20 mM MgCl<sub>2</sub>, 50 mM DTT), 1 mM of each dNTP and 20 units of RNase inhibitor. The enzyme was inactivated by heating the reaction mixture at 70 &#x000b0;C for 10 min.</p><p>The amplification was performed using PCR in a total volume of 25 &#x003bc;L containing 2.5xSYBR Green PCR Master Mix (Syntol), 200 nM of forward and reverse primers for each gene analyzed, and 10&#x02013;50 ng of the obtained cDNA in two replicates on a DT-Prime5 device according to the following program: 95 &#x000b0;C&#x02014;15 min, 40 cycles at 95 &#x000b0;C&#x02014;15 s, and 60&#x000b0;C&#x02014;30 s.</p></sec><sec id="sec2dot6-viruses-16-01944"><title>2.6. ELISA</title><p>Protein Kinase R (SEA520Hu, Cloud-Clone Corp., Katy, TX, USA) and cathepsins B, L, and S (Elabscience, Wuhan, China) were measured according to the manufacturer&#x02019;s instructions.</p></sec><sec id="sec2dot7-viruses-16-01944"><title>2.7. Analysis of Apoptosis in Cell Cultures</title><p>Cells were infected with serial dilutions of virus-containing material, as outlined in <xref rid="sec2dot2-viruses-16-01944" ref-type="sec">Section 2.2</xref>. Following infection, cells were trypsinized, counted using a Goryaev chamber, and washed with HBSS through gentle agitation or pipetting. Prior to analysis, binding buffer was prepared by diluting a concentrated 4&#x000d7; buffer solution with distilled water. The cells were resuspended in 100 &#x003bc;L of the 1&#x000d7; binding buffer at a density of (2&#x02013;5) &#x000d7; 10<sup>5</sup> cells/mL. To each 100 &#x003bc;L of cell suspension, 5 &#x003bc;L of Annexin V-FITC (BD Biosciences, San Diego, CA, USA) and 5 &#x003bc;L of propidium iodide (PI; BD Biosciences, USA) were added. The mixture was incubated for 30 min at room temperature, protected from light. After incubation, the sample volume was adjusted to 400 &#x003bc;L using the binding buffer. Cytometric analysis was performed on a Beckman Coulter EPICS XL Flow cytometer with SYSTEM II software 3.6.0 (Beckman Coulter, Miami, FL, USA). The intensity of the apoptosis reaction was assessed by the dual staining of cells with Annexin V-FITC and PI, analyzing 10,000 cell events per sample. The results were expressed as the percentage of apoptotic cells relative to the total cell population.</p><p>In parallel, caspase 3 activity was assessed using a colorimetric method according to the manufacturer&#x02019;s instructions (E-CKA311, Elabscience) 48 h after the inoculation of the virus. The infection scheme was identical to the scheme described above. The colorimetric signal from each sample was measured using a Varioskan Flash microplate reader (Thermo Fisher Scientific).</p></sec></sec><sec sec-type="results" id="sec3-viruses-16-01944"><title>3. Results</title><sec id="sec3dot1-viruses-16-01944"><title>3.1. Melanoma and Glioblastoma Cells Undergo Reovirus-Induced Oncolysis</title><p>Following the scheme applied in prior studies [<xref rid="B22-viruses-16-01944" ref-type="bibr">22</xref>,<xref rid="B24-viruses-16-01944" ref-type="bibr">24</xref>], we assessed the sensitivity of human tumor cells to reovirus-mediated oncolysis across four melanoma cell lines (mel Ibr, mel Il, mel Z, and mel Mtp) and five primary glioblastoma cell lines (Gbl13n, Gbl16n, Gbl17n, Gbl24n, and Gbl25n). Notable cytopathic effects, including reduced monolayer density and progressive cytoplasmic granulation, were evident as early as 48 hours post infection (h.p.i.) in tumor cells exposed to reovirus (<xref rid="app1-viruses-16-01944" ref-type="app">Supplementary Figure S1</xref>).</p><p>Cell viability following reovirus infection was quantified using the MTT assay at 24, 48, 72, 96, and 120 h.p.i. across a range of virus dilutions (10<sup>&#x02212;1</sup> to 10<sup>&#x02212;7</sup>). Higher MOIs resulted in a marked reduction in cell viability as early as 24 h.p.i. The effective dose (ED<sub>50</sub>) values varied among melanoma cell lines, with Mel Il, Mel Mtp, Mel Ibr, and Mel Z exhibiting ED<sub>50</sub> values of 0.7, 1.1, 2.7, and 3.1, respectively.</p><p>Primary glioblastoma cells displayed heterogeneity in sensitivity to reovirus-mediated oncolysis, with ED<sub>50</sub> values ranging from 2.7 to 4.3 log<sub>10</sub>PFU/mL at 120 h.p.i. Among these, Gbl17n cells exhibited the highest resistance, while Gbl24n, Gbl16n, Gbl25n, Gbl13n, and Gbl27n demonstrated progressively increasing sensitivity (<xref rid="viruses-16-01944-f001" ref-type="fig">Figure 1</xref>).</p><p>To evaluate the contribution of the reovirus replication to oncolysis, the heat-inactivated and UV-inactivated virus were used, since both lack the ability to replicate within target cells [<xref rid="B26-viruses-16-01944" ref-type="bibr">26</xref>]. Cell viability was measured using the MTT assay at 24&#x02013;120 h post treatment with inactivated virus (<xref rid="viruses-16-01944-f002" ref-type="fig">Figure 2</xref>).</p><p>UV inactivation preserved the cytotoxic potential of the reovirus, causing tumor cell death comparable to that induced by a replication-competent virus during early time points. In contrast, heat inactivation significantly reduced cytotoxicity, as evidenced by higher cell viability in treated cells. Thus, UV inactivation preserved the cytotoxic effect of the virus. However, the heat-inactivated virus preserved cell viability at approximately 100%, while the UV-inactivated virus reduced cell viability to 65&#x02013;70%. However, during further incubation, the replication-competent virus leveled off the difference. By 96 h.p.i., cells treated with replication-competent reovirus showed substantial reductions in viability, 25&#x02013;40%, whereas heat-inactivated virus treated cells retained 35&#x02013;75% viability. In contrast, UV-inactivated virus reduced cell viability similarly to the non-inactivated virus, confirming that the UV-treated virus retained a significant degree of oncolytic activity.</p><p>To further evaluate the specificity of reovirus-induced lysis, we tested its effects on non-tumor cells, immortalized hTERT-BJ fibroblasts, normal kidney epithelial (NKE) cells, and another malignant cell line, the human lung carcinoma cell line A549. These cell types demonstrated consistent resistance to reovirus infection across a 120 h cultivation period, as shown in <xref rid="viruses-16-01944-f003" ref-type="fig">Figure 3</xref>.</p><p>The ED<sub>50</sub> values for all cell lines used are summarized in <xref rid="viruses-16-01944-t001" ref-type="table">Table 1</xref>. This observed resistance in certain cell lines may stem from the absence of critical factors required for reovirus-induced oncolysis. Specifically, the inhibition of Protein Kinase R (PKR), a pivotal component of antiviral immunity, might be absent or insufficiently active in these resistant cells [<xref rid="B27-viruses-16-01944" ref-type="bibr">27</xref>]. Additionally, these cell types may fail to express the requisite receptors for reovirus on their cellular surface, thereby impeding the virus&#x02019;s ability to initiate infection [<xref rid="B28-viruses-16-01944" ref-type="bibr">28</xref>].</p></sec><sec id="sec3dot2-viruses-16-01944"><title>3.2. Protein Kinase R Expression Does Not Correlate with Sensitivity to Reovirus-Induced Oncolysis, While EGFR Gene Expression in Glioblastoma Cells Does</title><p>Among the melanoma cell lines analyzed, three, Mel Il, Mel Ibr, and Mel Z, harbored hyperactivating mutations in the <italic toggle="yes">BRAF</italic> gene, while one, Mel Mtp, carried a mutation in the <italic toggle="yes">NRAS</italic> gene. In melanoma cells, the activated RAS-signaling pathway is known to inhibit PKR activity through multiple mechanisms, leading in turn to impaired interferon (IFN) responses [<xref rid="B29-viruses-16-01944" ref-type="bibr">29</xref>]. Thus, the activated RAS-signaling pathway is considered to be one of the main mechanisms in tumor cells contributing to their sensitivity to reovirus and selective permissiveness [<xref rid="B30-viruses-16-01944" ref-type="bibr">30</xref>]. Consequently, PKR may be absent or less abundant in tumor cells relative to reovirus-resistant cells [<xref rid="B27-viruses-16-01944" ref-type="bibr">27</xref>].</p><p>To assess the potential correlation, we examined the production of the phosphorylated form of PKR (pPKR) in reovirus-infected cells considered in previous experiments (<xref rid="viruses-16-01944-f004" ref-type="fig">Figure 4</xref>). At an MOI of 1.0, pPKR production was significantly higher in NRAS-mutated Mel Mtp cells, as well as in Gbl16n and Gbl27n (<italic toggle="yes">p</italic> &#x0003c; 0.001) cells. Conversely, reduced pPKR levels were observed in two glioblastoma cells, Gbl13n and Gbl17n, as well as in the normal cell line, hTERT-BJ (<italic toggle="yes">p</italic> &#x0003c; 0.05). RAF-mutated melanoma cell lines, Mel Ibr, Mel Z, and Mel Il; two glioblastoma cells, Gbl24n and Gbl25n; and resistant cell lines, NKE and A549, showed no statistically significant pPKR induction of production following reovirus infection 24 h.p.i. (<italic toggle="yes">p</italic> &#x0003e; 0.05).</p><p>These findings indicate that the hyperactivation of the RAS-signaling pathway and the subsequent inhibition of PKR activity do not correlate with reovirus-induced oncolysis or selective tumor cell targeting.</p><p>In glioblastoma cells, previous studies have established that the epidermal growth factor receptor (EGFR) is overexpressed in approximately 60% of primary cases, associating with more aggressive tumor phenotypes [<xref rid="B31-viruses-16-01944" ref-type="bibr">31</xref>]. EGFR is a crucial player in cellular signaling: its ligand binding triggers receptor dimerization and tyrosine autophosphorylation, ultimately promoting cell proliferation [<xref rid="B32-viruses-16-01944" ref-type="bibr">32</xref>,<xref rid="B33-viruses-16-01944" ref-type="bibr">33</xref>]. On the other hand, EGFR has been identified as one of the key cell surface proteins recognized by reovirus, specifically binding to the N-terminal extracellular domain of EGFR, as demonstrated by Huang and colleagues [<xref rid="B34-viruses-16-01944" ref-type="bibr">34</xref>].</p><p>To explore the potential role of <italic toggle="yes">EGFR</italic> gene expression in reovirus sensitivity, previous transcriptome analysis was applied to primary glioblastoma cells used in this study. The results, shown in <xref rid="viruses-16-01944-f005" ref-type="fig">Figure 5</xref>, reveal notable heterogeneity in <italic toggle="yes">EGFR</italic> expression among the glioblastoma cell lines. In particular, Gbl13n and Gbl24n displayed a high <italic toggle="yes">EGFR</italic> expression, suggesting increased susceptibility to reovirus-mediated oncolysis, consistent with the receptor&#x02019;s role in facilitating viral entry. In contrast, the lower <italic toggle="yes">EGFR</italic> expression observed in Gbl17n correlated with the resistance to reovirus oncolysis identified earlier.</p></sec><sec id="sec3dot3-viruses-16-01944"><title>3.3. Melanoma and Glioblastoma Cells Support the Reovirus Replication</title><p>Although <italic toggle="yes">EGFR</italic> gene expression showed potential as a predictor of reovirus susceptibility, the link between susceptibility and permissiveness is not straightforward. While susceptibility refers to the initial entry of the virus into cells, permissiveness involves the ability of tumor cells to support the complete replication cycle of the virus, including viral genome replication, transcription, and the assembly of new virions.</p><p>To determine whether reovirus-mediated oncolysis in glioblastoma and melanoma cells is dependent on viral replication, or if the mere presence of viral RNA alone is sufficient to trigger cell death, we tracked the kinetics of viral RNA accumulation. The permissiveness was assessed using a qPCR-based potency assay allowing us to quantify viral RNA accumulation in infectious virions (<xref rid="viruses-16-01944-f006" ref-type="fig">Figure 6</xref>). Tumor cells were reinfected with reovirus at an MOI of 0.1, and viral RNA accumulation dynamics were monitored over 72 h for melanoma cells and 96 h for glioblastoma cells. In parallel, the replication capacity of functional reovirus was compared to that of heat- or UV-inactivated reovirus. For replication-competent reovirus, qPCR potency assay analysis revealed a time-dependent increase in viral RNA levels, indicating productive infection and, consequently, the permissiveness of tumor cells to reovirus. Conversely, cells infected with heat- or UV-inactivated virus showed no significant RNA accumulation, confirming that heat or UV treatment eliminated the replication capacity.</p><p>Thus, the increased cytotoxicity of the UV-inactivated virus was not directly tied to RNA replication. This is likely due to the cross-linking of surface proteins and damage to the viral genome caused by UV exposure, leading to the release of dsRNA during the infection and induction of helicase receptors, which in turn mediate cell death [<xref rid="B35-viruses-16-01944" ref-type="bibr">35</xref>].</p><p>The A549 cell line further demonstrated resistance to reovirus, as no replication was detected in this culture. However, the replication of reovirus in glioblastoma cells was also found to be minimal, with one cell line, Gbl24n, being unsupportive of the reoviral growth. Thus, these findings indicate that the oncolytic activity of reovirus in glioblastoma cells is not necessarily reliant on active replication.</p><p>In summary, all tested melanoma cell lines and four of the five glioblastoma cells demonstrated sensitivity to the Moscow strain of reovirus. In contrast, normal immortalized cell lines, human hTERT-BJ fibroblasts, NKE cells, and two tumor cell lines, A549 and Gbl17n, exhibited relative resistance to reovirus-mediated oncolysis. Furthermore, melanoma cell death strongly depended on the efficiency of viral RNA replication, as evidenced by the correlation between the kinetics of viral RNA accumulation in infected melanoma cell lines and the rate of cell lysis in contrast to cell death mediated by inactivated reovirus. In contrast to melanoma cell lines, cell death in primary glioblastoma cells appeared independent of replication efficiency.</p></sec><sec id="sec3dot4-viruses-16-01944"><title>3.4. Modulation of Cathepsin Activity as a Factor Mediating Oncolysis of Reovirus</title><p>To elucidate the mechanisms driving the oncolytic activity of the Moscow strain of reovirus, we investigated the role of cathepsin activity, a critical factor in the reovirus life cycle. Cathepsins mediate the proteolytic processing of the virus within the tumor cells or their microenvironment, enabling subsequent viral replication [<xref rid="B36-viruses-16-01944" ref-type="bibr">36</xref>,<xref rid="B37-viruses-16-01944" ref-type="bibr">37</xref>]. Tumor cells, in turn, overexpress cathepsins to promote metastasis, invasion, and angiogenesis [<xref rid="B38-viruses-16-01944" ref-type="bibr">38</xref>].</p><p>First, we considered the expression of cathepsin genes well known to contribute to glioblastoma development (<xref rid="viruses-16-01944-t002" ref-type="table">Table 2</xref>).</p><p>The most significantly abundant gene among all was the gene coding cathepsin B. The lowest levels of the cathepsin B gene expression were in cells Gbl17n and Gbl24n, which did not support reoviral replication. However, the statistical analysis revealed the cathepsin S gene as the most differentially expressed between responsive and nonresponsive cells to reovirus-mediated cell killing (<italic toggle="yes">p</italic> = 0.0012). The data were validated by qPCR-RT. Intriguingly, the gene coding cathepsin S was the only gene significantly upregulated among the studied genes after infection with reovirus (p (Spearman) = 4.55 &#x000d7; 10<sup>&#x02212;5</sup>) in all glioblastoma cell lines (<xref rid="viruses-16-01944-f007" ref-type="fig">Figure 7</xref>). It is known that cathepsin S played an important role in the regulation of autophagy and apoptosis in human glioblastoma cells; on the other hand, this may support acid-independent infection by some reoviruses [<xref rid="B39-viruses-16-01944" ref-type="bibr">39</xref>,<xref rid="B40-viruses-16-01944" ref-type="bibr">40</xref>].</p><p>To evaluate the contribution of cathepsin activity in melanoma and glioblastoma cells, we employed a selective inhibitor targeting cathepsins B, L, and S. First, we assessed the cytotoxicity of the inhibitor on tumor cells by an MTT assay (<xref rid="viruses-16-01944-f008" ref-type="fig">Figure 8</xref>). Working concentrations of 5 mM and 10 mM were selected for further experiments. At 5 mM, the inhibitor showed no toxic effect on tumor cells. However, at 10 mM, a slight reduction in cell viability relative to untreated controls was observed, although this difference was not statistically significant (<italic toggle="yes">p</italic> = 0.069).</p><p>At the next stage, the melanoma and glioblastoma cell lines previously identified as sensitive were infected with reovirus at MOIs of 0.1, 1.0, and 10, in the presence or absence of a selective cathepsin inhibitor. Untreated infected cells served as controls (<xref rid="viruses-16-01944-f009" ref-type="fig">Figure 9</xref>).</p><p>At 24 h.p.i., the presence of a cathepsin inhibitor significantly reduced the oncolytic activity of reovirus in all melanoma cells, as evidenced by a marked increase in cell viability compared to the control groups (<xref rid="viruses-16-01944-f009" ref-type="fig">Figure 9</xref>, upper panel). This effect was most pronounced in Mel Mtp cells, where viability in the presence of the 10 mM inhibitor remained equivalent to that of uninfected controls (100%), even at the highest MOI (MOI 10). In Mel Ibr cells, viability increased to 69% and 81% at MOIs of 10 and 1.0, respectively, compared to 43% and 57% in the control groups. A similar pattern was observed in Mel Il cells. However, at 72 h.p.i., these differences had completely leveled out for the higher MOIs, while for the MOI of 0.1, the difference was still significant (<italic toggle="yes">p</italic> = 0.024). The selected cathepsin inhibitor concentrations were sufficient to inhibit the oncolytic activity of reovirus with a MOI of 0.1, whereas at high MOIs, reovirus undergoes partial activation and successfully replicates during the next 48 h. Thus, higher MOIs may overwhelm the viral load that eventually surpasses the inhibitory effect of the cathepsin inhibitor.</p><p>For Gbl13n, Gbl16n, and Gbl25n glioblastoma cells, a similar pattern was observed (<xref rid="viruses-16-01944-f009" ref-type="fig">Figure 9</xref>, lower panel). Notably, a significant difference in viability was observed between the infected Gbl13n cells in the presence and absence of cathepsin inhibitor at all MOIs, while in Gbl16n and Gbl25n cells, only at higher MOIs (similar to melanoma cells). However, no significant difference was observed in Gbl24n and Gbl27n cells. Furthermore, <xref rid="viruses-16-01944-f006" ref-type="fig">Figure 6</xref> illustrates the significant reduction in the reoviral infectivity in Mel Ibr, Mel Mtp, Mel Z, Gbl13n, and Gbl25n cells pretreated with inhibitor, but not in Mel Il, Gbl16n, or Gbl27n cells at 4 h.p.i.</p><p>To confirm the inhibition specificity to the reovirus-mediated oncolysis, a protease inhibitor cocktail including a nonselective cathepsin inhibitor was similarly used. <xref rid="viruses-16-01944-f010" ref-type="fig">Figure 10</xref> shows Mel Il cell viability after infection with serial 10-fold dilutions of reovirus (MOI 10, 1.0, and 0.1) or in the presence of inhibitors (+Inh): specific (CatInh) or nonspecific (ProInh). The protease inhibitor cocktail had no toxic effect on tumor cells (<italic toggle="yes">p</italic> = 0.07) and no significant differences in viability of tumor cells infected with reovirus at all MOIs (<italic toggle="yes">p</italic> &#x0003e; 0.05).</p><p>The activity levels of cathepsins B, L, and S, key proteases involved in the proteolytic degradation of reovirus&#x02019;s outer capsid proteins, were assessed by ELISA (<xref rid="viruses-16-01944-f011" ref-type="fig">Figure 11</xref>). Reovirus particles are subjected to proteolytic degradation by cathepsins in the late endosome. However, several studies have reported the membrane-bound and secreted cathepsins B and L, which have not been shown to be involved in the proteolytic degradation of the outer capsid protein [<xref rid="B36-viruses-16-01944" ref-type="bibr">36</xref>,<xref rid="B37-viruses-16-01944" ref-type="bibr">37</xref>]. Thus, the levels of cathepsins were measured in supernatants as well as in cell lysates.</p><p>The levels of activity of the cathepsins intracellularly and in supernatants differed among cell lines. However, reovirus-sensitive cells tended to show higher levels of cathepsins B, L and S activity compared to reovirus-resistant tumor cells (A549) and non-tumor cells (hTERT-BJ and NKE). Thus, the lowest level of cathepsin L activity was observed for the reovirus-resistant lung carcinoma cell culture, A549, as well as non-tumors NKE and hTERT-BJ, both intracellularly and in supernatants. In contrast, reovirus-sensitive tumor cells exhibited significantly higher cathepsin L activity, particularly in the supernatants, with the exception of Mel Mtp cells and other conditionally resistant cell lines. The highest relative level of cathepsin B activity in supernatants was characteristic of Mel Z cells, as well as Gbl13n and Gbl25n, and intracellularly, Gbl13n, Gbl16n, and Gbl25n. Cathepsin B activity was absent in both the lysates and supernatants of hTERT-BJ cells, and was absent in the supernatants of Mel Mtp, Gbl24n, and NKE cells. Furthermore, cathepsin B activity was significantly higher in primary glioblastoma compared with melanoma cells in supernatants, but not in lysates, while for cathepsin L, no differences were observed. Considering the viability data of infected melanoma and glioblastoma (<xref rid="viruses-16-01944-f001" ref-type="fig">Figure 1</xref>) cells, together with control non-tumor cells (<xref rid="viruses-16-01944-f003" ref-type="fig">Figure 3</xref>), it was suggested that both cathepsins contribute to the reovirus infection of tumor cells, in contrast to cathepsin S. Furthermore, for the cells used in this study, the contribution of cathepsin L was more crucial, as cells remained permissive to reovirus-mediated oncolysis in the absence of cathepsin B activity. These results suggest that reoviral proteolytic disassembly by cathepsins is essential for reovirus-induced tumor cell killing. However, no correlation between the level of cathepsin activity and ED<sub>50</sub> was observed (<xref rid="viruses-16-01944-t001" ref-type="table">Table 1</xref>). Yet, these results indicate that the activity levels of cathepsins B and L in tumor cells can apparently be used as biomarkers to predict susceptibility to reovirus-induced cell death.</p></sec><sec id="sec3dot5-viruses-16-01944"><title>3.5. Apoptosis Induction in Melanoma and Glioblastoma Cells in Response to Reovirus Infection</title><p>To assess cell death, the activity of proapoptotic caspases in infected melanoma and glioblastoma cells was analyzed (<xref rid="viruses-16-01944-f012" ref-type="fig">Figure 12</xref>).</p><p>The level of caspase-3/7 activity 48 h.p.i. was significantly increased in glioblastoma cells, pretreated and untreated by a cathepsin inhibitor. No differences were observed between the two groups for Gbl13n and Gbl16n cells, in contrast to Gbl25n and Gbl27n cells. The most significant increase in caspase-3/7 activity was shown for glioblastoma cells incubated with UV-inactivated reovirus. Also, treatment with UV-inactivated reovirus significantly induced caspase-3/7 activation in all melanoma cell lines, indicating that apoptosis signaling was not defective. However, only Mel Il and Mel Z melanoma cells infected with competent reovirus showed a significant increase in caspase-3/7 activity compared to uninfected cells, while in Mel Mtp and Mel Ibr cells, the activity even decreased relative to uninfected cells. Based on these data, cell lines were clustered according to the induction of caspase-3/7 response.</p><p>Next, we performed a cytometric analysis of tumor cells at 24 h after infection in order to capture the early apoptotic events. Uninfected tumor cells, cells incubated with UV-inactivated reovirus, and cells infected with reovirus, pretreated and untreated with a cathepsin inhibitor, were stained with Annexin V and PI (<xref rid="viruses-16-01944-f013" ref-type="fig">Figure 13</xref>).</p><p>The proportions of Annexin V+/PI&#x02212; (suggesting early apoptosis) and Annexin V+/PI+ (suggesting late apoptosis or non-apoptotic death) cell populations were significantly higher compared to uninfected controls. However, in Mel Ibr and Mel Mtp reovirus-infected cells, the population of early apoptotic cells was notably lower than that of the late apoptotic population (<xref rid="viruses-16-01944-f013" ref-type="fig">Figure 13</xref>a,b), whereas no significant difference was observed in Mel Z and Mel Il cells (<xref rid="viruses-16-01944-f013" ref-type="fig">Figure 13</xref>c,d). Overall, the cytometric profiles for cells infected with replication-competent reovirus differed from those incubated with UV-inactivated, particularly in the increased induction of early apoptotic populations in the UV-infected cells. This observation was further supported by the caspase-3/7 activity assay. This difference suggests that replication-competent reovirus infection may disrupt apoptotic signaling, resulting in non-apoptotic cell death.</p><p>Thus, it was shown that different tumor cell lines reacted differently to reovirus infection: both apoptotic and non-apoptotic death markers can be characteristic for infected tumor cells. As noted above, neoplastic cells are characterized by specific mutations in genes encoding products of the interferon cascade, leading to the suppression of the interferon-induced inhibition of cell proliferation and, apparently, apoptosis signaling. However, when apoptosis is not possible, necroptosis can be triggered. Furthermore, these results highlight the cellular heterogeneity, although some cell lines can be clustered together.</p></sec></sec><sec sec-type="discussion" id="sec4-viruses-16-01944"><title>4. Discussion</title><p>Mammalian orthoreovirus (reovirus) is a member of the <italic toggle="yes">Spinareoviridae</italic> family, represented by non-enveloped 10-segmented double-stranded RNA viruses. Reovirus infection is widespread; strains serologically identical to human reoviruses have been isolated from a wide variety of animals [<xref rid="B20-viruses-16-01944" ref-type="bibr">20</xref>]. Reovirus infection often occurs in humans (with 50&#x02013;100% of adults showing seropositivity), but in most cases, it is subclinical. Despite its lack of pathogenicity in humans, reovirus displays selective oncolytic activity against malignant cells [<xref rid="B41-viruses-16-01944" ref-type="bibr">41</xref>]. The T3 Dearing (T3D) strain of reovirus is currently being tested in clinical trials for several types of cancers [<xref rid="B42-viruses-16-01944" ref-type="bibr">42</xref>,<xref rid="B43-viruses-16-01944" ref-type="bibr">43</xref>].</p><p>In this study, it was shown that the Moscow strain of reovirus effectively replicates in the human melanoma cell lines and primary glioblastoma cells tested, but not in normal human cells or A549 cells. The functional mechanisms of the oncolytic action of reovirus were studied, as well as the main factors of tumor cell sensitivity and resistance to viral oncolysis. Both pre- and post-entry events have been studied in an attempt to define biomarkers that will predict sensitivity or resistance to reoviral oncolysis. In particular, we analyzed PKR production in infected and uninfected cells, as well as <italic toggle="yes">EGFR</italic> gene expression in primary glioblastoma cells and the role of the cathepsins in determining virus mediated cytotoxicity in studied cells. Overall, our data support the results obtained in studies on the T3 Dearing (T3D) strain of reovirus.</p><p>Previous studies on the mechanism of reovirus selectivity against malignant and transformed cells showed that Ras signaling pathway activation, including epidermal growth factor receptor (EGFR) and mutated Ras, increased the sensitivity of cells to reovirus-induced cell killing [<xref rid="B28-viruses-16-01944" ref-type="bibr">28</xref>]. The activated Ras signaling in these cells was subsequently found to inhibit the function of PKR through multiple mechanisms preventing viral protein translation. Virus-derived double-stranded RNA binds and activates PKR, leading to the phosphorylation of eIF2&#x003b1;. Phosphorylated eIF2&#x003b1; suppresses translation in normal cells. Thus, in Ras-activated cells, dysfunctional PKR signaling allows reovirus replication and subsequent cell death [<xref rid="B11-viruses-16-01944" ref-type="bibr">11</xref>]. However, recent studies have demonstrated that reovirus efficiently replicates and kills Ras-activated tumor cells [<xref rid="B44-viruses-16-01944" ref-type="bibr">44</xref>]. Thus, these results indicate that there should be a more suitable mechanism as a biomarker for sensitivity to reovirus, compared with the Ras activation status [<xref rid="B41-viruses-16-01944" ref-type="bibr">41</xref>].</p><p>The overexpression of EGFR and consequent activation of the Ras signaling pathway is the dominant oncogenic process in glioblastoma and melanoma cells, respectively [<xref rid="B16-viruses-16-01944" ref-type="bibr">16</xref>,<xref rid="B31-viruses-16-01944" ref-type="bibr">31</xref>,<xref rid="B32-viruses-16-01944" ref-type="bibr">32</xref>,<xref rid="B33-viruses-16-01944" ref-type="bibr">33</xref>]. In normal cells, EGFR can be activated by epidermal growth factor, transforming growth factor &#x003b1;, or other ligands [<xref rid="B15-viruses-16-01944" ref-type="bibr">15</xref>]. Upon activation, the dimerization of the EGFR and autophosphorylation of tyrosine residues on the C-terminal domains of the receptor occurs, leading to the activation of proteins downstream in the RAS/RAF/MAPK signaling cascade [<xref rid="B45-viruses-16-01944" ref-type="bibr">45</xref>]. EGFR has been shown to be constitutively activated in cells of various epithelial tumors such as in non-small-cell lung cancer, colorectal cancer, and head and neck tumors [<xref rid="B46-viruses-16-01944" ref-type="bibr">46</xref>]. In glioblastoma cells, the <italic toggle="yes">EGFR</italic> gene is the most frequently amplified and overexpressed proto-oncogene. EGFR amplification is found in approximately 40&#x02013;50% of glioblastoma cases [<xref rid="B32-viruses-16-01944" ref-type="bibr">32</xref>,<xref rid="B33-viruses-16-01944" ref-type="bibr">33</xref>]. Thus, the sensitivity of glioblastoma cells to reovirus could depend on the signaling status in the EGFR/Ras/MAPK pathway.</p><p>The data obtained indicate that reovirus predominantly replicated in <italic toggle="yes">p53</italic>- and <italic toggle="yes">PTEN</italic>-mutated glioblastoma cells. We found that Gbl17n cells, the only glioblastoma cells resistant to reovirus-induced oncolysis, lacked <italic toggle="yes">EGFR</italic> gene expression compared to the other primary glioblastoma cells studied. However, we did not observe the correlation of <italic toggle="yes">EGFR</italic> gene expression with the reovirus sensitivity of these cells. Thus, <italic toggle="yes">EGFR</italic> gene expression is mandatory for viral infection, but cannot be considered a biomarker of reovirus selectivity. In this respect, the data are similar to those obtained in other studies [<xref rid="B41-viruses-16-01944" ref-type="bibr">41</xref>]. Previous studies reported that two mouse cell lines (NR6 and B82), expressing no EGFR, were relatively resistant to reovirus infection, but the same cell lines transfected with the gene encoding EGFR express significantly higher susceptibility. This enhancement of infection efficiency requires a functional EGFR since it was not observed in cells expressing a mutated EGFR as in tumor cells [<xref rid="B47-viruses-16-01944" ref-type="bibr">47</xref>].</p><p>On the other hand, reovirus predominantly replicated in NRAS- and BRAF-mutated melanoma cells. An analysis of PKR production revealed no correlation with reovirus-mediated oncolytic efficiencies. Indeed, reovirus efficiently killed the Mel Mtp melanoma cell line that showed significant levels of PKR activation, while A549 and NKE cells that failed to activate PKR were resistant to reovirus infection. Similar results have been reported using other malignant cells [<xref rid="B48-viruses-16-01944" ref-type="bibr">48</xref>].</p><p>Furthermore, viral replication does not always correlate with cytotoxicity. While the studied cells could support the initial entry of the virus, these cells may lack the ability to support the complete replication cycle of the virus, including viral genome replication, transcription, and the assembly of new virions. Thus, other cellular factors should explain the differences in the cell viabilities following reovirus infection among tumor cell lines.</p><p>Virion uncoating is a critical step in the life cycle of reoviruses. After the virus enters the cell, virions undergo proteolysis by cathepsin proteases in endosomes [<xref rid="B36-viruses-16-01944" ref-type="bibr">36</xref>], resulting in the formation of infectious subvirion particles [<xref rid="B49-viruses-16-01944" ref-type="bibr">49</xref>]. In natural enteric reovirus infections, infectious subvirion particles can also be formed as a result of proteolysis by extracellular proteases, such as gastrointestinal proteases, trypsin, and chymotrypsin [<xref rid="B37-viruses-16-01944" ref-type="bibr">37</xref>].</p><p>Previous studies demonstrated that cathepsins B and L are highly important for infection with reovirus [<xref rid="B50-viruses-16-01944" ref-type="bibr">50</xref>,<xref rid="B51-viruses-16-01944" ref-type="bibr">51</xref>]. Furthermore, it was demonstrated that cathepsin S is involved in reovirus infection [<xref rid="B40-viruses-16-01944" ref-type="bibr">40</xref>]. Proteases, such as cathepsin family members and matrix metalloproteinases, are often upregulated in tumors and may also be involved in processes other than proteolytic activity during invasion that are associated with tumor progression, such as proliferation, survival, angiogenesis, senescence, apoptosis, and autophagy [<xref rid="B52-viruses-16-01944" ref-type="bibr">52</xref>]. In particular, cathepsins A [<xref rid="B53-viruses-16-01944" ref-type="bibr">53</xref>], B [<xref rid="B54-viruses-16-01944" ref-type="bibr">54</xref>], C [<xref rid="B55-viruses-16-01944" ref-type="bibr">55</xref>], D [<xref rid="B56-viruses-16-01944" ref-type="bibr">56</xref>], K [<xref rid="B57-viruses-16-01944" ref-type="bibr">57</xref>], L [<xref rid="B58-viruses-16-01944" ref-type="bibr">58</xref>], S [<xref rid="B56-viruses-16-01944" ref-type="bibr">56</xref>], and X/Z [<xref rid="B59-viruses-16-01944" ref-type="bibr">59</xref>] are known to be involved in the neoplastic transformation of normal glial cells and associated with immune cells infiltration, immunosuppression, and other processes. Indeed, it was shown that cathepsin B signaling is a driver of glioblastoma malignancy [<xref rid="B60-viruses-16-01944" ref-type="bibr">60</xref>]. Furthermore, TGF-beta, which is often overexpressed in a tumor microenvironment, is involved in the induction of the expression of cathepsins B and L, which are important for reovirus infection [<xref rid="B61-viruses-16-01944" ref-type="bibr">61</xref>]. In addition, Ras activation is involved in upregulation in the activity of cathepsin family members in tumor cells, suggesting that Ras-activated tumor cells often exhibit high cathepsin activities. Indeed, Y. Terasawa and colleagues demonstrated that Ras-activated tumor cells with low activities of cathepsins B and L are resistant to reovirus, whereas reovirus efficiently exhibited cell killing even though Ras was inactivated only if the cells showed high activity levels of cathepsins B and L [<xref rid="B50-viruses-16-01944" ref-type="bibr">50</xref>]. Thus, oncolytic reoviruses exploit specific tumor-associated proteases for proteolytic activation.</p><p>As it was mentioned previously, the Moscow strain of reovirus was isolated in MA-104 cells in trypsin-containing medium. The presence of trypsin in the growth medium was a mandatory condition for reovirus reproduction at early passages in MA-104 cells, as the absence of trypsin lead to aborted cytopathic effects [<xref rid="B20-viruses-16-01944" ref-type="bibr">20</xref>]. However, long-term reoviral passaging in MA-104 cells allowed us to progressively reduce the trypsin concentration in the growth medium. Therefore, the laboratory-adapted Moscow strain reproduction relies on the presence of trypsin in particular and proteases in general in the growth medium. Q.F. Lin and colleagues demonstrated that the majority of naturally circulating reoviruses rely on intestinal proteases from specific species for uncoating and infection; however, the existence of low-frequency mutations among the natural quasi-species likely enables rapid adaptation to intracellular proteases under selective pressure [<xref rid="B62-viruses-16-01944" ref-type="bibr">62</xref>]. Thus, different strains may require different tumor-associated proteases for virus activation. Considering this, the contribution of specific cathepsins to oncolysis mediated by the Moscow strain was also assessed. The reovirus-permissive tumor cell lines (cells susceptible to reovirus oncolysis) exhibited a tendency to express higher levels of cathepsin B and L activities than the reovirus-resistant tumor cell lines. Furthermore, the viability of tumor cells following reovirus infection was not restored by the cathepsin inhibitors to the same degree as the viability of the uninfected tumor cells. In addition to cathepsins B and L as essential factors for the reoviral proteolytic disassembly, the significant upregulation of genes coding cathepsin S in cells sensitive to reovirus-mediated oncolysis was revealed in this work, supporting the results obtained in previous studies [<xref rid="B40-viruses-16-01944" ref-type="bibr">40</xref>,<xref rid="B50-viruses-16-01944" ref-type="bibr">50</xref>,<xref rid="B51-viruses-16-01944" ref-type="bibr">51</xref>]. However, additional studies using siRNA or CRISPR-Cas9 are needed to better define the role of cathepsins in the replication of the Moscow strain of reovirus. Beyond cathepsins B, L, and S, other cellular proteases may also contribute to reovirus-mediated tumor lysis depending on the strain of the reovirus. Naturally circulating reoviruses can vary in their susceptibility to proteolysis by intestinal enzymes from different source species [<xref rid="B62-viruses-16-01944" ref-type="bibr">62</xref>]. Furthermore, recently, A. Mohamed and colleagues demonstrated substantial differences in the replication capabilities of highly related T3D laboratory strains in cancer cells in vitro. At the 48-hour post-infection time point, which represents only two rounds of reovirus replication, these differences were already evident, highlighting significant strain-specific variability in replication and tumor cell spread [<xref rid="B63-viruses-16-01944" ref-type="bibr">63</xref>,<xref rid="B64-viruses-16-01944" ref-type="bibr">64</xref>]. This underscores the importance of directly comparing the T3D and Moscow strains of reovirus in future studies.</p><p>In summary, this study demonstrated that the efficiency of reovirus-mediated tumor cell lysis depends on the activity levels of cathepsins, particularly of B, L and S, in tumor cells, suggesting that the activity levels of cathepsins B, L, and S could further be studied as predictive biomarkers for reovirus-mediated oncolysis. These factors may account for the high selectivity of reovirus toward tumor cells with a minimal toxic effect on the surrounding healthy tissues.</p></sec><sec sec-type="conclusions" id="sec5-viruses-16-01944"><title>5. Conclusions</title><p>This study demonstrates that the Moscow strain of reovirus effectively replicates in human melanoma cell lines and most primary glioblastoma cells, while exhibiting no replication in non-malignant human cells or the A549 cell line. Notably, all melanoma cell lines tested were sensitive to reovirus infection, whereas sensitivity varied among primary glioblastoma cells. No virus reproduction was observed in non-malignant cells or the A549 cell line. Moreover, reovirus-infected tumor cells exhibited distinct mechanisms of cell death, highlighting the complexity of reovirus-mediated oncolysis.</p><p>The functional mechanisms underlying the oncolytic efficacy of the Moscow strain were investigated, identifying key factors contributing to sensitivity and resistance to viral oncolysis. Tumor cell-derived cathepsins B, L, and S were shown to play pivotal roles in facilitating reovirus-mediated oncolysis, as pretreatment with a specific inhibitor significantly delayed the cytotoxic effects of the virus in melanoma and glioblastoma cells.</p><p>Thus, these findings underscore the potential of the Moscow strain of reovirus as a selective and effective oncolytic agent, with promising applications in combination therapies targeting metastatic melanoma and glioblastoma.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-viruses-16-01944"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at <uri xlink:href="https://www.mdpi.com/article/10.3390/v16121944/s1">https://www.mdpi.com/article/10.3390/v16121944/s1</uri>: Table S1: Characteristics of melanoma cells used in the study; Figure S1: The cytopathic effect of reovirus, Moscow strain, on melanoma cells at 48 h post infection.</p><supplementary-material id="viruses-16-01944-s001" position="float" content-type="local-data"><media xlink:href="viruses-16-01944-s001.zip"/></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>Conceptualization and experiment design, Y.A. and E.F.; validation, E.F.; experiment assistance, E.N., O.S. (Olesya Sagimbaeva), P.S., A.A. and Y.Z.; flow cytometry, M.G.; resources, O.S. (Olga Susova), A.M. and A.B.; data curation, Y.A.; writing&#x02014;original draft preparation, Y.A. and E.N.; writing&#x02014;review and editing, E.N., E.F. and T.N.; supervision, V.Z.; project administration, O.S. (Oxana Svitich); funding acquisition, T.N. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>All subjects gave their informed consent before they participated in the study. The study was conducted in accordance with the Declaration of Helsinki, and the protocol was approved by the Ethics Committee of the Mechnikov Research Institute for Vaccines and Sera. The protocol for establishing primary cells from the surgical resection or biopsies of confirmed GBM cases was approved by the Local Ethics Committee of the N.N. Blokhin National Medical Research Center of Oncology (protocol code 7; 27 July 2023). All patients gave their informed consent.</p></notes><notes><title>Informed Consent Statement</title><p>Informed consent was obtained from all subjects involved in the study.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>Data are contained within the article and <xref rid="app1-viruses-16-01944" ref-type="app">Supplementary Materials</xref>. Additional information is available on request.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.</p></notes><ref-list><title>References</title><ref id="B1-viruses-16-01944"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Barchuk</surname><given-names>A.</given-names></name>
<name><surname>Belyaev</surname><given-names>A.</given-names></name>
<name><surname>Gretsova</surname><given-names>O.</given-names></name>
<name><surname>Tursun-Zade</surname><given-names>R.</given-names></name>
<name><surname>Moshina</surname><given-names>N.</given-names></name>
<name><surname>Znaor</surname><given-names>A.</given-names></name>
</person-group><article-title>History and current status of cancer registration in Russia</article-title><source>Cancer Epidemiol.</source><year>2021</year><volume>73</volume><fpage>101963</fpage><pub-id pub-id-type="doi">10.1016/j.canep.2021.101963</pub-id><pub-id pub-id-type="pmid">34089992</pub-id>
</element-citation></ref><ref id="B2-viruses-16-01944"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schadendorf</surname><given-names>D.</given-names></name>
<name><surname>van Akkooi</surname><given-names>A.C.J.</given-names></name>
<name><surname>Berking</surname><given-names>C.</given-names></name>
<name><surname>Griewank</surname><given-names>K.G.</given-names></name>
<name><surname>Gutzmer</surname><given-names>R.</given-names></name>
<name><surname>Hauschild</surname><given-names>A.</given-names></name>
<name><surname>Stang</surname><given-names>A.</given-names></name>
<name><surname>Roesch</surname><given-names>A.</given-names></name>
<name><surname>Ugurel</surname><given-names>S.</given-names></name>
</person-group><article-title>Melanoma</article-title><source>Lancet</source><year>2018</year><volume>392</volume><fpage>971</fpage><lpage>984</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(18)31559-9</pub-id><pub-id pub-id-type="pmid">30238891</pub-id>
</element-citation></ref><ref id="B3-viruses-16-01944"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rios</surname><given-names>S.A.</given-names></name>
<name><surname>Oyervides</surname><given-names>S.</given-names></name>
<name><surname>Uribe</surname><given-names>D.</given-names></name>
<name><surname>Reyes</surname><given-names>A.M.</given-names></name>
<name><surname>Fanniel</surname><given-names>V.</given-names></name>
<name><surname>Vazquez</surname><given-names>J.</given-names></name>
<name><surname>Keniry</surname><given-names>M.</given-names></name>
</person-group><article-title>Emerging Therapies for Glioblastoma</article-title><source>Cancers</source><year>2024</year><volume>16</volume><elocation-id>1485</elocation-id><pub-id pub-id-type="doi">10.3390/cancers16081485</pub-id><pub-id pub-id-type="pmid">38672566</pub-id>
</element-citation></ref><ref id="B4-viruses-16-01944"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Torrisi</surname><given-names>F.</given-names></name>
<name><surname>Alberghina</surname><given-names>C.</given-names></name>
<name><surname>D&#x02019;Aprile</surname><given-names>S.</given-names></name>
<name><surname>Pavone</surname><given-names>A.M.</given-names></name>
<name><surname>Longhitano</surname><given-names>L.</given-names></name>
<name><surname>Giallongo</surname><given-names>S.</given-names></name>
<name><surname>Tibullo</surname><given-names>D.</given-names></name>
<name><surname>Di Rosa</surname><given-names>M.</given-names></name>
<name><surname>Zappal&#x000e0;</surname><given-names>A.</given-names></name>
<name><surname>Cammarata</surname><given-names>F.P.</given-names></name>
<etal/>
</person-group><article-title>The Hallmarks of Glioblastoma: Heterogeneity, Intercellular Crosstalk and Molecular Signature of Invasiveness and Progression</article-title><source>Biomedicines</source><year>2022</year><volume>10</volume><elocation-id>806</elocation-id><pub-id pub-id-type="doi">10.3390/biomedicines10040806</pub-id><pub-id pub-id-type="pmid">35453557</pub-id>
</element-citation></ref><ref id="B5-viruses-16-01944"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mess&#x000e9;</surname><given-names>M.</given-names></name>
<name><surname>Bernhard</surname><given-names>C.</given-names></name>
<name><surname>Foppolo</surname><given-names>S.</given-names></name>
<name><surname>Thomas</surname><given-names>L.</given-names></name>
<name><surname>Marchand</surname><given-names>P.</given-names></name>
<name><surname>Herold-Mende</surname><given-names>C.</given-names></name>
<name><surname>Idbaih</surname><given-names>A.</given-names></name>
<name><surname>Kessler</surname><given-names>H.</given-names></name>
<name><surname>Etienne-Selloum</surname><given-names>N.</given-names></name>
<name><surname>Ochoa</surname><given-names>C.</given-names></name>
<etal/>
</person-group><article-title>Hypoxia-driven heterogeneous expression of &#x003b1;5 integrin in glioblastoma stem cells is linked to HIF-2&#x003b1;</article-title><source>Biochim. Biophys. Acta Mol. Basis Dis.</source><year>2024</year><volume>8</volume><elocation-id>167471</elocation-id><pub-id pub-id-type="doi">10.1016/j.bbadis.2024.167471</pub-id><pub-id pub-id-type="pmid">39154793</pub-id>
</element-citation></ref><ref id="B6-viruses-16-01944"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Russell</surname><given-names>S.J.</given-names></name>
<name><surname>Peng</surname><given-names>K.W.</given-names></name>
<name><surname>Bell</surname><given-names>J.C.</given-names></name>
</person-group><article-title>Oncolytic virotherapy</article-title><source>Nat. Biotechnol.</source><year>2012</year><volume>30</volume><fpage>658</fpage><lpage>670</lpage><pub-id pub-id-type="doi">10.1038/nbt.2287</pub-id><pub-id pub-id-type="pmid">22781695</pub-id>
</element-citation></ref><ref id="B7-viruses-16-01944"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Martuza</surname><given-names>R.L.</given-names></name>
<name><surname>Malick</surname><given-names>A.</given-names></name>
<name><surname>Markert</surname><given-names>J.M.</given-names></name>
<name><surname>Ruffner</surname><given-names>K.L.</given-names></name>
<name><surname>Coen</surname><given-names>D.M.</given-names></name>
</person-group><article-title>Experimental therapy of human glioma by means of a genetically engineered virus mutant</article-title><source>Science</source><year>1991</year><volume>252</volume><fpage>854</fpage><lpage>856</lpage><pub-id pub-id-type="doi">10.1126/science.1851332</pub-id><pub-id pub-id-type="pmid">1851332</pub-id>
</element-citation></ref><ref id="B8-viruses-16-01944"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Suryawanshi</surname><given-names>Y.R.</given-names></name>
<name><surname>Schulze</surname><given-names>A.J.</given-names></name>
</person-group><article-title>Oncolytic Viruses for Malignant Glioma: On the Verge of Success?</article-title><source>Viruses</source><year>2021</year><volume>13</volume><elocation-id>1294</elocation-id><pub-id pub-id-type="doi">10.3390/v13071294</pub-id><pub-id pub-id-type="pmid">34372501</pub-id>
</element-citation></ref><ref id="B9-viruses-16-01944"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Galanis</surname><given-names>E.</given-names></name>
<name><surname>Markovic</surname><given-names>S.N.</given-names></name>
<name><surname>Suman</surname><given-names>V.J.</given-names></name>
<name><surname>Nuovo</surname><given-names>G.J.</given-names></name>
<name><surname>Vile</surname><given-names>R.G.</given-names></name>
<name><surname>Kottke</surname><given-names>T.J.</given-names></name>
<name><surname>Nevala</surname><given-names>W.K.</given-names></name>
<name><surname>Thompson</surname><given-names>M.A.</given-names></name>
<name><surname>Lewis</surname><given-names>J.E.</given-names></name>
<name><surname>Rumilla</surname><given-names>K.M.</given-names></name>
<etal/>
</person-group><article-title>Phase II trial of intravenous administration of Reolysin(<sup>&#x000ae;</sup>) (Reovirus Serotype-3-dearing Strain) in patients with metastatic melanoma</article-title><source>Mol. Ther.</source><year>2012</year><volume>10</volume><fpage>1998</fpage><lpage>2003</lpage><pub-id pub-id-type="doi">10.1038/mt.2012.146</pub-id><pub-id pub-id-type="pmid">22871663</pub-id>
</element-citation></ref><ref id="B10-viruses-16-01944"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Phillips</surname><given-names>M.B.</given-names></name>
<name><surname>Stuart</surname><given-names>J.D.</given-names></name>
<name><surname>Rodr&#x000ed;guez Stewart</surname><given-names>R.M.</given-names></name>
<name><surname>Berry</surname><given-names>J.T.</given-names></name>
<name><surname>Mainou</surname><given-names>B.A.</given-names></name>
<name><surname>Boehme</surname><given-names>K.W.</given-names></name>
</person-group><article-title>Current understanding of reovirus oncolysis mechanisms</article-title><source>Oncolytic Virother.</source><year>2018</year><volume>7</volume><fpage>53</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.2147/OV.S143808</pub-id><pub-id pub-id-type="pmid">29942799</pub-id>
</element-citation></ref><ref id="B11-viruses-16-01944"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gong</surname><given-names>J.</given-names></name>
<name><surname>Mita</surname><given-names>M.M.</given-names></name>
</person-group><article-title>Activated ras signaling pathways and reovirus oncolysis: An update on the mechanism of preferential reovirus replication in cancer cells</article-title><source>Front. Oncol.</source><year>2014</year><volume>4</volume><elocation-id>167</elocation-id><pub-id pub-id-type="doi">10.3389/fonc.2014.00167</pub-id><pub-id pub-id-type="pmid">25019061</pub-id>
</element-citation></ref><ref id="B12-viruses-16-01944"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bourhill</surname><given-names>T.</given-names></name>
<name><surname>Mori</surname><given-names>Y.</given-names></name>
<name><surname>Rancourt</surname><given-names>D.E.</given-names></name>
<name><surname>Shmulevitz</surname><given-names>M.</given-names></name>
<name><surname>Johnston</surname><given-names>R.N.</given-names></name>
</person-group><article-title>Going (Reo)Viral: Factors Promoting Successful Reoviral Oncolytic Infection</article-title><source>Viruses</source><year>2018</year><volume>10</volume><elocation-id>421</elocation-id><pub-id pub-id-type="doi">10.3390/v10080421</pub-id><pub-id pub-id-type="pmid">30103501</pub-id>
</element-citation></ref><ref id="B13-viruses-16-01944"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Strong</surname><given-names>J.E.</given-names></name>
<name><surname>Tang</surname><given-names>D.</given-names></name>
<name><surname>Lee</surname><given-names>P.W.</given-names></name>
</person-group><article-title>Evidence that the epidermal growth factor receptor on host cells confers reovirus infection efficiency</article-title><source>Virology</source><year>1993</year><volume>197</volume><fpage>405</fpage><lpage>411</lpage><pub-id pub-id-type="doi">10.1006/viro.1993.1602</pub-id><pub-id pub-id-type="pmid">8212574</pub-id>
</element-citation></ref><ref id="B14-viruses-16-01944"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Strong</surname><given-names>J.E.</given-names></name>
<name><surname>Lee</surname><given-names>P.W.</given-names></name>
</person-group><article-title>The v-erbB oncogene confers enhanced cellular susceptibility to reovirus infection</article-title><source>J. Virol.</source><year>1996</year><volume>70</volume><fpage>612</fpage><lpage>616</lpage><pub-id pub-id-type="doi">10.1128/jvi.70.1.612-616.1996</pub-id><pub-id pub-id-type="pmid">8523580</pub-id>
</element-citation></ref><ref id="B15-viruses-16-01944"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wells</surname><given-names>A.</given-names></name>
</person-group><article-title>EGF receptor</article-title><source>Int. J. Biochem. Cell Biol.</source><year>1999</year><volume>31</volume><fpage>637</fpage><lpage>643</lpage><pub-id pub-id-type="doi">10.1016/S1357-2725(99)00015-1</pub-id><pub-id pub-id-type="pmid">10404636</pub-id>
</element-citation></ref><ref id="B16-viruses-16-01944"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gou</surname><given-names>H.-F.</given-names></name>
<name><surname>Li</surname><given-names>X.</given-names></name>
<name><surname>Qiu</surname><given-names>M.</given-names></name>
<name><surname>Cheng</surname><given-names>K.</given-names></name>
<name><surname>Li</surname><given-names>L.-H.</given-names></name>
<name><surname>Dong</surname><given-names>H.</given-names></name>
<name><surname>Chen</surname><given-names>Y.</given-names></name>
<name><surname>Tang</surname><given-names>Y.</given-names></name>
<name><surname>Gao</surname><given-names>F.</given-names></name>
<name><surname>Zhao</surname><given-names>F.</given-names></name>
<etal/>
</person-group><article-title>Epidermal Growth Factor Receptor (EGFR)-RAS Signaling Pathway in Penile Squamous Cell Carcinoma</article-title><source>PLoS ONE</source><year>2013</year><volume>8</volume><elocation-id>e62175</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0062175</pub-id><pub-id pub-id-type="pmid">23637996</pub-id>
</element-citation></ref><ref id="B17-viruses-16-01944"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Campbell</surname><given-names>S.L.</given-names></name>
<name><surname>Khosravi-Far</surname><given-names>R.</given-names></name>
<name><surname>Rossman</surname><given-names>K.L.</given-names></name>
<name><surname>Clark</surname><given-names>G.J.</given-names></name>
<name><surname>Der</surname><given-names>C.J.</given-names></name>
</person-group><article-title>Increasing complexity of Ras signaling</article-title><source>Oncogene</source><year>1998</year><volume>17</volume><fpage>1395</fpage><lpage>1413</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1202174</pub-id><pub-id pub-id-type="pmid">9779987</pub-id>
</element-citation></ref><ref id="B18-viruses-16-01944"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Van Den Wollenberg</surname><given-names>D.J.</given-names></name>
<name><surname>Van Den Hengel</surname><given-names>S.K.</given-names></name>
<name><surname>Dautzenberg</surname><given-names>I.J.</given-names></name>
<name><surname>Kranenburg</surname><given-names>O.</given-names></name>
<name><surname>Hoeben</surname><given-names>R.C.</given-names></name>
</person-group><article-title>Modification of mammalian reoviruses for use as oncolytic agents</article-title><source>Expert. Opin. Biol. Ther.</source><year>2009</year><volume>12</volume><fpage>1509</fpage><lpage>1520</lpage><pub-id pub-id-type="doi">10.1517/14712590903307370</pub-id><pub-id pub-id-type="pmid">19916732</pub-id>
</element-citation></ref><ref id="B19-viruses-16-01944"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gong</surname><given-names>J.</given-names></name>
<name><surname>Sachdev</surname><given-names>E.</given-names></name>
<name><surname>Mita</surname><given-names>A.C.</given-names></name>
<name><surname>Mita</surname><given-names>M.M.</given-names></name>
</person-group><article-title>Clinical development of reovirus for cancer therapy: An oncolytic virus with immune-mediated antitumor activity</article-title><source>World J. Methodol.</source><year>2016</year><volume>6</volume><fpage>25</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.5662/wjm.v6.i1.25</pub-id><pub-id pub-id-type="pmid">27019795</pub-id>
</element-citation></ref><ref id="B20-viruses-16-01944"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Faisuloev</surname><given-names>E.B.</given-names></name>
<name><surname>Korchevaya</surname><given-names>E.P.</given-names></name>
<name><surname>Markov</surname><given-names>D.V.</given-names></name>
<name><surname>Petrusha</surname><given-names>O.A.</given-names></name>
<name><surname>Zverev</surname><given-names>V.V.</given-names></name>
</person-group><article-title>The problem of cell cultures contamination with mammalian Orthoreoviruses</article-title><source>J. Microbiol. Epidemiol. Immunobiol.</source><year>2018</year><volume>95</volume><fpage>104</fpage><lpage>107</lpage><pub-id pub-id-type="doi">10.36233/0372-9311-2018-5-104-107</pub-id></element-citation></ref><ref id="B21-viruses-16-01944"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Faizuloev</surname><given-names>E.</given-names></name>
<name><surname>Mintaev</surname><given-names>R.</given-names></name>
<name><surname>Petrusha</surname><given-names>O.</given-names></name>
<name><surname>Marova</surname><given-names>A.</given-names></name>
<name><surname>Smirnova</surname><given-names>D.</given-names></name>
<name><surname>Ammour</surname><given-names>Y.</given-names></name>
<name><surname>Meskina</surname><given-names>E.</given-names></name>
<name><surname>Sergeev</surname><given-names>O.</given-names></name>
<name><surname>Zhavoronok</surname><given-names>S.</given-names></name>
<name><surname>Karaulov</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>New approach of genetic characterization of group A rotaviruses by the nanopore sequencing method</article-title><source>J. Virol. Methods</source><year>2021</year><volume>292</volume><fpage>114114</fpage><pub-id pub-id-type="doi">10.1016/j.jviromet.2021.114114</pub-id><pub-id pub-id-type="pmid">33662411</pub-id>
</element-citation></ref><ref id="B22-viruses-16-01944"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ammour</surname><given-names>Y.</given-names></name>
<name><surname>Susova</surname><given-names>O.</given-names></name>
<name><surname>Krasnov</surname><given-names>G.</given-names></name>
<name><surname>Nikolaeva</surname><given-names>E.</given-names></name>
<name><surname>Varachev</surname><given-names>V.</given-names></name>
<name><surname>Schetinina</surname><given-names>Y.</given-names></name>
<name><surname>Gavrilova</surname><given-names>M.</given-names></name>
<name><surname>Mitrofanov</surname><given-names>A.</given-names></name>
<name><surname>Poletaeva</surname><given-names>A.</given-names></name>
<name><surname>Bekyashev</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>Transcriptome Analysis of Human Glioblastoma Cells Susceptible to Infection with the Leningrad-16 Vaccine Strain of Measles Virus</article-title><source>Viruses</source><year>2022</year><volume>14</volume><elocation-id>2433</elocation-id><pub-id pub-id-type="doi">10.3390/v14112433</pub-id><pub-id pub-id-type="pmid">36366531</pub-id>
</element-citation></ref><ref id="B23-viruses-16-01944"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Arbatskiy</surname><given-names>M.</given-names></name>
<name><surname>Balandin</surname><given-names>D.</given-names></name>
<name><surname>Churov</surname><given-names>A.</given-names></name>
<name><surname>Varachev</surname><given-names>V.</given-names></name>
<name><surname>Nikolaeva</surname><given-names>E.</given-names></name>
<name><surname>Mitrofanov</surname><given-names>A.</given-names></name>
<name><surname>Bekyashev</surname><given-names>A.</given-names></name>
<name><surname>Tkacheva</surname><given-names>O.</given-names></name>
<name><surname>Susova</surname><given-names>O.</given-names></name>
<name><surname>Nasedkina</surname><given-names>T.</given-names></name>
</person-group><article-title>Intratumoral Cell Heterogeneity in Patient-Derived Glioblastoma Cell Lines Revealed by Single-Cell RNA-Sequencing</article-title><source>Int. J. Mol. Sci.</source><year>2024</year><volume>25</volume><elocation-id>8472</elocation-id><pub-id pub-id-type="doi">10.3390/ijms25158472</pub-id><pub-id pub-id-type="pmid">39126040</pub-id>
</element-citation></ref><ref id="B24-viruses-16-01944"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ammour</surname><given-names>Y.</given-names></name>
<name><surname>Ryabaya</surname><given-names>O.</given-names></name>
<name><surname>Shchetinina</surname><given-names>Y.</given-names></name>
<name><surname>Prokofeva</surname><given-names>E.</given-names></name>
<name><surname>Gavrilova</surname><given-names>M.</given-names></name>
<name><surname>Khochenkov</surname><given-names>D.</given-names></name>
<name><surname>Vorobyev</surname><given-names>D.</given-names></name>
<name><surname>Faizuloev</surname><given-names>E.</given-names></name>
<name><surname>Shohin</surname><given-names>I.</given-names></name>
<name><surname>Zverev</surname><given-names>V.V.</given-names></name>
<etal/>
</person-group><article-title>The Susceptibility of Human Melanoma Cells to Infection with the Leningrad-16 Vaccine Strain of Measles Virus</article-title><source>Viruses</source><year>2020</year><volume>12</volume><elocation-id>173</elocation-id><pub-id pub-id-type="doi">10.3390/v12020173</pub-id><pub-id pub-id-type="pmid">32033013</pub-id>
</element-citation></ref><ref id="B25-viruses-16-01944"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ranheim</surname><given-names>T.</given-names></name>
<name><surname>Mathis</surname><given-names>P.K.</given-names></name>
<name><surname>Joelsson</surname><given-names>D.B.</given-names></name>
<name><surname>Smith</surname><given-names>M.E.</given-names></name>
<name><surname>Campbell</surname><given-names>K.M.</given-names></name>
<name><surname>Lucas</surname><given-names>G.</given-names></name>
<name><surname>Barmat</surname><given-names>S.</given-names></name>
<name><surname>Melissen</surname><given-names>E.</given-names></name>
<name><surname>Benz</surname><given-names>R.</given-names></name>
<name><surname>Lewis</surname><given-names>J.A.</given-names></name>
<etal/>
</person-group><article-title>Development and application of a quantitative RT-PCR potency assay for a pentavalent rotavirus vaccine (RotaTeq)</article-title><source>J. Virol. Methods</source><year>2006</year><volume>131</volume><fpage>193</fpage><lpage>201</lpage><pub-id pub-id-type="doi">10.1016/j.jviromet.2005.08.013</pub-id><pub-id pub-id-type="pmid">16214228</pub-id>
</element-citation></ref><ref id="B26-viruses-16-01944"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Loh</surname><given-names>P.C.</given-names></name>
<name><surname>Oie</surname><given-names>H.K.</given-names></name>
</person-group><article-title>Growth characteristics of reovirus type 2: Ultraviolet light inactivated virion preparations and cell death</article-title><source>Arch. F&#x000fc;r Die Gesamte Virusforsch.</source><year>2005</year><volume>26</volume><fpage>197</fpage><lpage>208</lpage><pub-id pub-id-type="doi">10.1007/BF01242372</pub-id></element-citation></ref><ref id="B27-viruses-16-01944"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fernandes</surname><given-names>J.</given-names></name>
</person-group><article-title>Oncogenes: The passport for viral oncolysis through PKR inhibition</article-title><source>Biomark. Cancer</source><year>2016</year><volume>8</volume><fpage>101</fpage><lpage>110</lpage><pub-id pub-id-type="doi">10.4137/BIC.S33378</pub-id><pub-id pub-id-type="pmid">27486347</pub-id>
</element-citation></ref><ref id="B28-viruses-16-01944"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Strong</surname><given-names>J.E.</given-names></name>
<name><surname>Coffey</surname><given-names>M.C.</given-names></name>
<name><surname>Tang</surname><given-names>D.</given-names></name>
<name><surname>Sabinin</surname><given-names>P.</given-names></name>
<name><surname>Lee</surname><given-names>P.W.</given-names></name>
</person-group><article-title>The molecular basis of viral oncolysis: Usurpation of the Ras signaling pathway by reovirus</article-title><source>EMBO J.</source><year>1998</year><volume>17</volume><fpage>3351</fpage><lpage>3362</lpage><pub-id pub-id-type="doi">10.1093/emboj/17.12.3351</pub-id><pub-id pub-id-type="pmid">9628872</pub-id>
</element-citation></ref><ref id="B29-viruses-16-01944"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Battcock</surname><given-names>S.M.</given-names></name>
<name><surname>Collier</surname><given-names>T.W.</given-names></name>
<name><surname>Zu</surname><given-names>D.</given-names></name>
<name><surname>Hirasawa</surname><given-names>K.</given-names></name>
</person-group><article-title>Negative regulation of the alpha interferon-induced antiviral response by the Ras/Raf/MEK pathway</article-title><source>J. Virol.</source><year>2006</year><volume>80</volume><fpage>4422</fpage><lpage>4430</lpage><pub-id pub-id-type="doi">10.1128/JVI.80.9.4422-4430.2006</pub-id><pub-id pub-id-type="pmid">16611902</pub-id>
</element-citation></ref><ref id="B30-viruses-16-01944"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shmulevitz</surname><given-names>M.</given-names></name>
<name><surname>Pan</surname><given-names>L.Z.</given-names></name>
<name><surname>Garant</surname><given-names>K.</given-names></name>
<name><surname>Pan</surname><given-names>D.</given-names></name>
<name><surname>Lee</surname><given-names>P.W.</given-names></name>
</person-group><article-title>Oncogenic Ras promotes reovirus spread by suppressing IFN-beta production through negative regulation of RIG-I signaling</article-title><source>Cancer Res.</source><year>2010</year><volume>70</volume><fpage>4912</fpage><lpage>4921</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-09-4676</pub-id><pub-id pub-id-type="pmid">20501842</pub-id>
</element-citation></ref><ref id="B31-viruses-16-01944"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xu</surname><given-names>H.</given-names></name>
<name><surname>Zong</surname><given-names>H.</given-names></name>
<name><surname>Ma</surname><given-names>C.</given-names></name>
<name><surname>Ming</surname><given-names>X.</given-names></name>
<name><surname>Shang</surname><given-names>M.</given-names></name>
<name><surname>Li</surname><given-names>K.</given-names></name>
<name><surname>He</surname><given-names>X.</given-names></name>
<name><surname>Du</surname><given-names>H.</given-names></name>
<name><surname>Cao</surname><given-names>L.</given-names></name>
</person-group><article-title>Epidermal growth factor receptor in glioblastoma</article-title><source>Oncol. Lett.</source><year>2017</year><volume>14</volume><fpage>512</fpage><lpage>516</lpage><pub-id pub-id-type="doi">10.3892/ol.2017.6221</pub-id><pub-id pub-id-type="pmid">28693199</pub-id>
</element-citation></ref><ref id="B32-viruses-16-01944"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Varachev</surname><given-names>V.O.</given-names></name>
<name><surname>Susova</surname><given-names>O.Y.</given-names></name>
<name><surname>Mitrofanov</surname><given-names>A.A.</given-names></name>
<name><surname>Krasnov</surname><given-names>G.S.</given-names></name>
<name><surname>Naskhletashvili</surname><given-names>D.R.</given-names></name>
<name><surname>Ammour</surname><given-names>Y.I.</given-names></name>
<name><surname>Bezhanova</surname><given-names>S.D.</given-names></name>
<name><surname>Sevyan</surname><given-names>N.V.</given-names></name>
<name><surname>Prozorenko</surname><given-names>E.V.</given-names></name>
<name><surname>Bekyashev</surname><given-names>A.K.</given-names></name>
<etal/>
</person-group><article-title>Structural alterations of the EGFR gene in glioblastoma samples as a prognostic factor and molecular target for therapy</article-title><source>Adv. Mol. Oncol.</source><year>2024</year><volume>11</volume><fpage>68</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.17650/2313-805X-2024-11-3-68-78</pub-id></element-citation></ref><ref id="B33-viruses-16-01944"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Saadeh</surname><given-names>F.S.</given-names></name>
<name><surname>Mahfouz</surname><given-names>R.</given-names></name>
<name><surname>Assi</surname><given-names>H.I.</given-names></name>
</person-group><article-title>EGFR as a clinical marker in glioblastomas and other gliomas</article-title><source>Int. J. Biol. Markers.</source><year>2018</year><volume>33</volume><fpage>22</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.5301/ijbm.5000301</pub-id><pub-id pub-id-type="pmid">28885661</pub-id>
</element-citation></ref><ref id="B34-viruses-16-01944"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tang</surname><given-names>D.</given-names></name>
<name><surname>Strong</surname><given-names>J.E.</given-names></name>
<name><surname>Lee</surname><given-names>P.W.</given-names></name>
</person-group><article-title>Recognition of the epidermal growth factor receptor by reovirus</article-title><source>Virology</source><year>1993</year><volume>197</volume><fpage>412</fpage><lpage>414</lpage><pub-id pub-id-type="doi">10.1006/viro.1993.1603</pub-id><pub-id pub-id-type="pmid">8212575</pub-id>
</element-citation></ref><ref id="B35-viruses-16-01944"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>W.</given-names></name>
<name><surname>Wang</surname><given-names>W.H.</given-names></name>
<name><surname>Azadzoi</surname><given-names>K.</given-names></name>
</person-group><article-title>Activation of innate antiviral immune response via double-stranded RNA-dependent RLR receptor-mediated necroptosis</article-title><source>Sci. Rep.</source><year>2016</year><volume>6</volume><elocation-id>22550</elocation-id><pub-id pub-id-type="doi">10.1038/srep22550</pub-id><pub-id pub-id-type="pmid">26935990</pub-id>
</element-citation></ref><ref id="B36-viruses-16-01944"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Alain</surname><given-names>T.</given-names></name>
<name><surname>Kim</surname><given-names>T.S.</given-names></name>
<name><surname>Lun</surname><given-names>X.</given-names></name>
<name><surname>Liacini</surname><given-names>A.</given-names></name>
<name><surname>Schiff</surname><given-names>L.A.</given-names></name>
<name><surname>Senger</surname><given-names>D.L.</given-names></name>
<name><surname>Forsyth</surname><given-names>P.A.</given-names></name>
</person-group><article-title>Proteolytic disassembly is a critical determinant for reovirus oncolysis</article-title><source>Mol. Ther.</source><year>2007</year><volume>15</volume><fpage>1512</fpage><lpage>1521</lpage><pub-id pub-id-type="doi">10.1038/sj.mt.6300207</pub-id><pub-id pub-id-type="pmid">17519890</pub-id>
</element-citation></ref><ref id="B37-viruses-16-01944"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Golden</surname><given-names>J.W.</given-names></name>
<name><surname>Linke</surname><given-names>J.</given-names></name>
<name><surname>Schmechel</surname><given-names>S.</given-names></name>
<name><surname>Thoemke</surname><given-names>K.</given-names></name>
<name><surname>Schiff</surname><given-names>L.A.</given-names></name>
</person-group><article-title>Addition of exogenous protease facilitates reovirus infection in many restrictive cells</article-title><source>J. Virol.</source><year>2002</year><volume>76</volume><fpage>7430</fpage><lpage>7443</lpage><pub-id pub-id-type="doi">10.1128/JVI.76.15.7430-7443.2002</pub-id><pub-id pub-id-type="pmid">12097555</pub-id>
</element-citation></ref><ref id="B38-viruses-16-01944"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tan</surname><given-names>G.J.</given-names></name>
<name><surname>Peng</surname><given-names>Z.K.</given-names></name>
<name><surname>Lu</surname><given-names>J.P.</given-names></name>
<name><surname>Tang</surname><given-names>F.Q.</given-names></name>
</person-group><article-title>Cathepsins mediate tumor metastasis</article-title><source>World J. Biol. Chem.</source><year>2013</year><volume>4</volume><fpage>91</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.4331/wjbc.v4.i4.91</pub-id><pub-id pub-id-type="pmid">24340132</pub-id>
</element-citation></ref><ref id="B39-viruses-16-01944"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wei</surname><given-names>L.</given-names></name>
<name><surname>Shao</surname><given-names>N.</given-names></name>
<name><surname>Peng</surname><given-names>Y.</given-names></name>
<name><surname>Zhou</surname><given-names>P.</given-names></name>
</person-group><article-title>Inhibition of Cathepsin S Restores TGF-&#x003b2;-induced Epithelial-to-mesenchymal Transition and Tight Junction Turnover in Glioblastoma Cells</article-title><source>J. Cancer.</source><year>2021</year><volume>12</volume><fpage>1592</fpage><lpage>1603</lpage><pub-id pub-id-type="doi">10.7150/jca.50631</pub-id><pub-id pub-id-type="pmid">33613746</pub-id>
</element-citation></ref><ref id="B40-viruses-16-01944"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Golden</surname><given-names>J.W.</given-names></name>
<name><surname>Bahe</surname><given-names>J.A.</given-names></name>
<name><surname>Lucas</surname><given-names>W.T.</given-names></name>
<name><surname>Nibert</surname><given-names>M.L.</given-names></name>
<name><surname>Schiff</surname><given-names>L.A.</given-names></name>
</person-group><article-title>Cathepsin S supports acid-independent infection by some reoviruses</article-title><source>J. Biol. Chem.</source><year>2004</year><volume>279</volume><fpage>8547</fpage><lpage>8557</lpage><pub-id pub-id-type="doi">10.1074/jbc.M309758200</pub-id><pub-id pub-id-type="pmid">14670972</pub-id>
</element-citation></ref><ref id="B41-viruses-16-01944"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Twigger</surname><given-names>K.</given-names></name>
<name><surname>Roulstone</surname><given-names>V.</given-names></name>
<name><surname>Kyula</surname><given-names>J.</given-names></name>
<name><surname>Karapanagiotou</surname><given-names>E.M.</given-names></name>
<name><surname>Syrigos</surname><given-names>K.N.</given-names></name>
<name><surname>Morgan</surname><given-names>R.</given-names></name>
<name><surname>White</surname><given-names>C.</given-names></name>
<name><surname>Bhide</surname><given-names>S.</given-names></name>
<name><surname>Nuovo</surname><given-names>G.</given-names></name>
<name><surname>Coffey</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Reovirus exerts potent oncolytic effects in head and neck cancer cell lines that are independent of signalling in the EGFR pathway</article-title><source>BMC Cancer</source><year>2012</year><volume>12</volume><elocation-id>368</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2407-12-368</pub-id><pub-id pub-id-type="pmid">22920673</pub-id>
</element-citation></ref><ref id="B42-viruses-16-01944"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>White</surname><given-names>C.L.</given-names></name>
<name><surname>Twigger</surname><given-names>K.</given-names></name>
<name><surname>Vidal</surname><given-names>L.</given-names></name>
</person-group><article-title>Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial</article-title><source>Gene Ther.</source><year>2008</year><volume>15</volume><fpage>911</fpage><lpage>920</lpage><pub-id pub-id-type="doi">10.1038/gt.2008.21</pub-id><pub-id pub-id-type="pmid">18323793</pub-id>
</element-citation></ref><ref id="B43-viruses-16-01944"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vidal</surname><given-names>L.</given-names></name>
<name><surname>Pandha</surname><given-names>H.S.</given-names></name>
<name><surname>Yap</surname><given-names>T.A.</given-names></name>
<name><surname>White</surname><given-names>C.L.</given-names></name>
<name><surname>Twigger</surname><given-names>K.</given-names></name>
<name><surname>Vile</surname><given-names>R.G.</given-names></name>
<name><surname>Melcher</surname><given-names>A.</given-names></name>
<name><surname>Coffey</surname><given-names>M.</given-names></name>
<name><surname>Harrington</surname><given-names>K.J.</given-names></name>
<name><surname>DeBono</surname><given-names>J.S.</given-names></name>
</person-group><article-title>A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer</article-title><source>Clin. Cancer Res.</source><year>2008</year><volume>14</volume><fpage>7127</fpage><lpage>7137</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-08-0524</pub-id><pub-id pub-id-type="pmid">18981012</pub-id>
</element-citation></ref><ref id="B44-viruses-16-01944"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Song</surname><given-names>L.</given-names></name>
<name><surname>Ohnuma</surname><given-names>T.</given-names></name>
<name><surname>Gelman</surname><given-names>I.H.</given-names></name>
<name><surname>Holland</surname><given-names>J.F.</given-names></name>
</person-group><article-title>Reovirus infection of cancer cells is not due to activated Ras pathway</article-title><source>Cancer Gene Ther.</source><year>2009</year><volume>16</volume><fpage>382</fpage><pub-id pub-id-type="doi">10.1038/cgt.2008.84</pub-id><pub-id pub-id-type="pmid">18949012</pub-id>
</element-citation></ref><ref id="B45-viruses-16-01944"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jones</surname><given-names>S.</given-names></name>
<name><surname>Rappoport</surname><given-names>J.Z.</given-names></name>
</person-group><article-title>Interdependent epidermal growth factor receptor signalling and trafficking</article-title><source>Int. J. Biochem. Cell Biol.</source><year>2014</year><volume>51</volume><fpage>23</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1016/j.biocel.2014.03.014</pub-id><pub-id pub-id-type="pmid">24681003</pub-id>
</element-citation></ref><ref id="B46-viruses-16-01944"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sigismund</surname><given-names>S.</given-names></name>
<name><surname>Avanzato</surname><given-names>D.</given-names></name>
<name><surname>Lanzetti</surname><given-names>L.</given-names></name>
</person-group><article-title>Emerging functions of the EGFR in cancer</article-title><source>Mol. Oncol.</source><year>2018</year><volume>12</volume><fpage>3</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1002/1878-0261.12155</pub-id><pub-id pub-id-type="pmid">29124875</pub-id>
</element-citation></ref><ref id="B47-viruses-16-01944"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Volovat</surname><given-names>S.R.</given-names></name>
<name><surname>Scripcariu</surname><given-names>D.V.</given-names></name>
<name><surname>Vasilache</surname><given-names>I.A.</given-names></name>
<name><surname>Stolniceanu</surname><given-names>C.R.</given-names></name>
<name><surname>Volovat</surname><given-names>C.</given-names></name>
<name><surname>Augustin</surname><given-names>I.G.</given-names></name>
<name><surname>Volovat</surname><given-names>C.C.</given-names></name>
<name><surname>Ostafe</surname><given-names>M.-R.</given-names></name>
<name><surname>Andreea-Voichi&#x0021b;a</surname><given-names>S.-G.</given-names></name>
<name><surname>Bejusca-Vieriu</surname><given-names>T.</given-names></name>
<etal/>
</person-group><article-title>Oncolytic Virotherapy: A New Paradigm in Cancer Immunotherapy</article-title><source>Int. J. Mol. Sci.</source><year>2024</year><volume>25</volume><elocation-id>1180</elocation-id><pub-id pub-id-type="doi">10.3390/ijms25021180</pub-id><pub-id pub-id-type="pmid">38256250</pub-id>
</element-citation></ref><ref id="B48-viruses-16-01944"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>P.</given-names></name>
<name><surname>Samuel</surname><given-names>C.E.</given-names></name>
</person-group><article-title>Protein kinase PKR plays a stimulus- and virus-dependent role in apoptotic death and virus multiplication in human cells</article-title><source>J. Virol.</source><year>2007</year><volume>81</volume><fpage>8192</fpage><lpage>8200</lpage><pub-id pub-id-type="doi">10.1128/JVI.00426-07</pub-id><pub-id pub-id-type="pmid">17522227</pub-id>
</element-citation></ref><ref id="B49-viruses-16-01944"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Doyle</surname><given-names>J.D.</given-names></name>
<name><surname>Danthi</surname><given-names>P.</given-names></name>
<name><surname>Kendall</surname><given-names>E.A.</given-names></name>
<name><surname>Ooms</surname><given-names>L.S.</given-names></name>
<name><surname>Wetzel</surname><given-names>J.D.</given-names></name>
</person-group><article-title>Dermody TS. Molecular determinants of proteolytic disassembly of the reovirus outer capsid</article-title><source>J. Biol. Chem.</source><year>2012</year><volume>287</volume><fpage>8029</fpage><lpage>8038</lpage><pub-id pub-id-type="doi">10.1074/jbc.M111.334854</pub-id><pub-id pub-id-type="pmid">22253447</pub-id>
</element-citation></ref><ref id="B50-viruses-16-01944"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Terasawa</surname><given-names>Y.</given-names></name>
<name><surname>Hotani</surname><given-names>T.</given-names></name>
<name><surname>Katayama</surname><given-names>Y.</given-names></name>
<name><surname>Tachibana</surname><given-names>M.</given-names></name>
<name><surname>Mizuguchi</surname><given-names>H.</given-names></name>
<name><surname>Sakurai</surname><given-names>F.</given-names></name>
</person-group><article-title>Activity levels of cathepsins B and L in tumor cells are a biomarker for efficacy of reovirus-mediated tumor cell killing</article-title><source>Cancer Gene Ther.</source><year>2015</year><volume>22</volume><fpage>188</fpage><lpage>197</lpage><pub-id pub-id-type="doi">10.1038/cgt.2015.4</pub-id><pub-id pub-id-type="pmid">25633482</pub-id>
</element-citation></ref><ref id="B51-viruses-16-01944"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sakurai</surname><given-names>F.</given-names></name>
<name><surname>Inoue</surname><given-names>S.</given-names></name>
<name><surname>Kaminade</surname><given-names>T.</given-names></name>
<name><surname>Hotani</surname><given-names>T.</given-names></name>
<name><surname>Katayama</surname><given-names>Y.</given-names></name>
<name><surname>Hosoyamada</surname><given-names>E.</given-names></name>
<name><surname>Terasawa</surname><given-names>Y.</given-names></name>
<name><surname>Tachibana</surname><given-names>M.</given-names></name>
<name><surname>Mizuguchi</surname><given-names>H.</given-names></name>
</person-group><article-title>Cationic liposome-mediated delivery of reovirus enhances the tumor cell-killing efficiencies of reovirus in reovirus-resistant tumor cells</article-title><source>Int. J. Pharm.</source><year>2017</year><volume>524</volume><fpage>238</fpage><lpage>247</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2017.04.006</pub-id><pub-id pub-id-type="pmid">28389364</pub-id>
</element-citation></ref><ref id="B52-viruses-16-01944"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kos</surname><given-names>J.</given-names></name>
<name><surname>Mitrovi&#x00107;</surname><given-names>A.</given-names></name>
<name><surname>Peri&#x00161;i&#x00107; Nanut</surname><given-names>M.</given-names></name>
<name><surname>Pi&#x00161;lar</surname><given-names>A.</given-names></name>
</person-group><article-title>Lysosomal peptidases-intriguing roles in cancer progression and neurodegeneration</article-title><source>FEBS Open Bio</source><year>2022</year><volume>12</volume><fpage>708</fpage><lpage>738</lpage><pub-id pub-id-type="doi">10.1002/2211-5463.13372</pub-id></element-citation></ref><ref id="B53-viruses-16-01944"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>M.</given-names></name>
<name><surname>Huang</surname><given-names>J.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Nie</surname><given-names>Q.</given-names></name>
<name><surname>Zhang</surname><given-names>X.</given-names></name>
<name><surname>Yang</surname><given-names>Y.</given-names></name>
<name><surname>Mao</surname><given-names>G.</given-names></name>
</person-group><article-title>Cathepsin a upregulation in glioma: A potential therapeutic target associated with immune infiltration</article-title><source>J. Med. Biochem.</source><year>2022</year><volume>41</volume><fpage>459</fpage><lpage>465</lpage><pub-id pub-id-type="doi">10.5937/jomb0-35677</pub-id><pub-id pub-id-type="pmid">36381072</pub-id>
</element-citation></ref><ref id="B54-viruses-16-01944"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ma</surname><given-names>K.</given-names></name>
<name><surname>Chen</surname><given-names>X.</given-names></name>
<name><surname>Liu</surname><given-names>W.</given-names></name>
<name><surname>Chen</surname><given-names>S.</given-names></name>
<name><surname>Yang</surname><given-names>C.</given-names></name>
<name><surname>Yang</surname><given-names>J.</given-names></name>
</person-group><article-title>CTSB is a negative prognostic biomarker and therapeutic target associated with immune cells infiltration and immunosuppression in gliomas</article-title><source>Sci. Rep.</source><year>2022</year><volume>12</volume><fpage>4295</fpage><pub-id pub-id-type="doi">10.1038/s41598-022-08346-2</pub-id><pub-id pub-id-type="pmid">35277559</pub-id>
</element-citation></ref><ref id="B55-viruses-16-01944"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cheng</surname><given-names>X.</given-names></name>
<name><surname>Ren</surname><given-names>Z.</given-names></name>
<name><surname>Liu</surname><given-names>Z.</given-names></name>
<name><surname>Sun</surname><given-names>X.</given-names></name>
<name><surname>Qian</surname><given-names>R.</given-names></name>
<name><surname>Cao</surname><given-names>C.</given-names></name>
<name><surname>Liu</surname><given-names>B.</given-names></name>
<name><surname>Wang</surname><given-names>J.</given-names></name>
<name><surname>Wang</surname><given-names>H.</given-names></name>
<name><surname>Guo</surname><given-names>Y.</given-names></name>
<etal/>
</person-group><article-title>Cysteine cathepsin C: A novel potential biomarker for the diagnosis and prognosis of glioma</article-title><source>Cancer Cell Int.</source><year>2022</year><volume>22</volume><fpage>53</fpage><pub-id pub-id-type="doi">10.1186/s12935-021-02417-6</pub-id><pub-id pub-id-type="pmid">35109832</pub-id>
</element-citation></ref><ref id="B56-viruses-16-01944"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Oldak</surname><given-names>L.</given-names></name>
<name><surname>Milewska</surname><given-names>P.</given-names></name>
<name><surname>Chludzinska-Kasperuk</surname><given-names>S.</given-names></name>
<name><surname>Grubczak</surname><given-names>K.</given-names></name>
<name><surname>Reszec</surname><given-names>J.</given-names></name>
<name><surname>Gorodkiewicz</surname><given-names>E.</given-names></name>
</person-group><article-title>Cathepsin B, D and S as Potential Biomarkers of Brain Glioma Malignancy</article-title><source>J. Clin. Med.</source><year>2022</year><volume>11</volume><elocation-id>6763</elocation-id><pub-id pub-id-type="doi">10.3390/jcm11226763</pub-id><pub-id pub-id-type="pmid">36431239</pub-id>
</element-citation></ref><ref id="B57-viruses-16-01944"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Verbov&#x00161;ek</surname><given-names>U.</given-names></name>
<name><surname>Motaln</surname><given-names>H.</given-names></name>
<name><surname>Rotter</surname><given-names>A.</given-names></name>
<name><surname>Atai</surname><given-names>N.A.</given-names></name>
<name><surname>Gruden</surname><given-names>K.</given-names></name>
<name><surname>Van Noorden</surname><given-names>C.J.</given-names></name>
<name><surname>Lah</surname><given-names>T.T.</given-names></name>
</person-group><article-title>Expression Analysis of All Protease Genes Reveals Cathepsin K to Be Overexpressed in Glioblastoma</article-title><source>PLoS ONE</source><year>2014</year><volume>9</volume><elocation-id>e111819</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0111819</pub-id><pub-id pub-id-type="pmid">25356585</pub-id>
</element-citation></ref><ref id="B58-viruses-16-01944"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Strojnik</surname><given-names>T.</given-names></name>
<name><surname>Kavalar</surname><given-names>R.</given-names></name>
<name><surname>Trinkaus</surname><given-names>M.</given-names></name>
<name><surname>Lah</surname><given-names>T.T.</given-names></name>
</person-group><article-title>Cathepsin L in glioma progression: Comparison with cathepsin B</article-title><source>Cancer Detect. Prev.</source><year>2005</year><volume>29</volume><fpage>448</fpage><lpage>455</lpage><pub-id pub-id-type="doi">10.1016/j.cdp.2005.07.006</pub-id><pub-id pub-id-type="pmid">16183211</pub-id>
</element-citation></ref><ref id="B59-viruses-16-01944"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>H.</given-names></name>
<name><surname>Peng</surname><given-names>J.</given-names></name>
<name><surname>Huang</surname><given-names>L.</given-names></name>
<name><surname>Ruan</surname><given-names>D.</given-names></name>
<name><surname>Li</surname><given-names>Y.</given-names></name>
<name><surname>Yuan</surname><given-names>F.</given-names></name>
<name><surname>Tu</surname><given-names>Z.</given-names></name>
<name><surname>Huang</surname><given-names>K.</given-names></name>
<name><surname>Zhu</surname><given-names>X.</given-names></name>
</person-group><article-title>The role of lysosomal peptidases in glioma immune escape: Underlying mechanisms and therapeutic strategies</article-title><source>Front. Immunol.</source><year>2023</year><volume>14</volume><elocation-id>1154146</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2023.1154146</pub-id><pub-id pub-id-type="pmid">37398678</pub-id>
</element-citation></ref><ref id="B60-viruses-16-01944"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Norton</surname><given-names>E.S.</given-names></name>
<name><surname>Whaley</surname><given-names>L.A.</given-names></name>
<name><surname>Jones</surname><given-names>V.K.</given-names></name>
<name><surname>Brooks</surname><given-names>M.M.</given-names></name>
<name><surname>Russo</surname><given-names>M.N.</given-names></name>
<name><surname>Morderer</surname><given-names>D.</given-names></name>
<name><surname>Jessen</surname><given-names>E.</given-names></name>
<name><surname>Schiapparelli</surname><given-names>P.</given-names></name>
<name><surname>Ramos-Fresnedo</surname><given-names>A.</given-names></name>
<name><surname>Zarco</surname><given-names>N.</given-names></name>
<etal/>
</person-group><article-title>Cell-specific crosstalk proteomics reveals cathepsin B signaling as a driver of glioblastoma malignancy near the subventricular zone</article-title><source>Sci. Adv.</source><year>2024</year><volume>10</volume><fpage>eadn1607</fpage><pub-id pub-id-type="doi">10.1126/sciadv.adn1607</pub-id><pub-id pub-id-type="pmid">39110807</pub-id>
</element-citation></ref><ref id="B61-viruses-16-01944"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ishigami</surname><given-names>I.</given-names></name>
<name><surname>Shuwari</surname><given-names>N.</given-names></name>
<name><surname>Kaminade</surname><given-names>T.</given-names></name>
<name><surname>Mizuguchi</surname><given-names>H.</given-names></name>
<name><surname>Sakurai</surname><given-names>F.</given-names></name>
</person-group><article-title>A TGF&#x003b2; Signaling Inhibitor, SB431542, Inhibits Reovirus-mediated Lysis of Human Hepatocellular Carcinoma Cells in a TGF&#x003b2;-independent Manner</article-title><source>Anticancer. Res.</source><year>2021</year><volume>41</volume><fpage>2431</fpage><lpage>2440</lpage><pub-id pub-id-type="doi">10.21873/anticanres.15018</pub-id><pub-id pub-id-type="pmid">33952468</pub-id>
</element-citation></ref><ref id="B62-viruses-16-01944"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lin</surname><given-names>Q.F.</given-names></name>
<name><surname>Wong</surname><given-names>C.X.L.</given-names></name>
<name><surname>Eaton</surname><given-names>H.E.</given-names></name>
<name><surname>Pang</surname><given-names>X.</given-names></name>
<name><surname>Shmulevitz</surname><given-names>M.</given-names></name>
</person-group><article-title>Reovirus genomic diversity confers plasticity for protease utility during adaptation to intracellular uncoating</article-title><source>J. Virol.</source><year>2023</year><volume>97</volume><fpage>e00828-23</fpage><pub-id pub-id-type="doi">10.1128/jvi.00828-23</pub-id><pub-id pub-id-type="pmid">37747236</pub-id>
</element-citation></ref><ref id="B63-viruses-16-01944"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mohamed</surname><given-names>A.</given-names></name>
<name><surname>Smiley</surname><given-names>J.R.</given-names></name>
<name><surname>Shmulevitz</surname><given-names>M.</given-names></name>
</person-group><article-title>Polymorphisms in the Most Oncolytic Reovirus Strain Confer Enhanced Cell Attachment, Transcription, and Single-Step Replication Kinetics</article-title><source>J. Virol.</source><year>2020</year><volume>94</volume><fpage>e01937-19</fpage><pub-id pub-id-type="doi">10.1128/JVI.01937-19</pub-id><pub-id pub-id-type="pmid">31776267</pub-id>
</element-citation></ref><ref id="B64-viruses-16-01944"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mohamed</surname><given-names>A.</given-names></name>
<name><surname>Clements</surname><given-names>D.R.</given-names></name>
<name><surname>Gujar</surname><given-names>S.A.</given-names></name>
<name><surname>Lee</surname><given-names>P.W.</given-names></name>
<name><surname>Smiley</surname><given-names>J.R.</given-names></name>
<name><surname>Shmulevitz</surname><given-names>M.</given-names></name>
</person-group><article-title>Single Amino Acid Differences between Closely Related Reovirus T3D Lab Strains Alter Oncolytic Potency In Vitro and In Vivo</article-title><source>J. Virol.</source><year>2020</year><volume>94</volume><fpage>e01688-19</fpage><pub-id pub-id-type="doi">10.1128/JVI.01688-19</pub-id><pub-id pub-id-type="pmid">31748391</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="viruses-16-01944-f001"><label>Figure 1</label><caption><p>The viability of four melanoma cell cultures and five primary glioblastoma cell cultures incubated with reovirus, Moscow strain, at varying MOIs. The X-axis displays the virus viral titer (PFU/mL) and a control uninfected culture, while the Y-axis indicates cell viability (%). Different colors of the curves represent various time intervals post infection. Cell viability corresponded to the optical density values for the infected cell culture, expressed as a percentage of the values for a similar uninfected culture immediately before infection (0 h). Error bars denote standard deviation.</p></caption><graphic xlink:href="viruses-16-01944-g001a" position="float"/><graphic xlink:href="viruses-16-01944-g001b" position="float"/></fig><fig position="float" id="viruses-16-01944-f002"><label>Figure 2</label><caption><p>(<bold>Upper panel</bold>) A hierarchically clustered heatmap showing the viability of melanoma cell lines and primary glioblastoma cells 120 h after infection with the Moscow strain of reovirus. Cells were infected at different MOIs (1.5, 4.5, 5.5, and 6.5 PFU/mL). The color scale represents cell viability as a percentage, ranging from 30% (coral) to 100% (navy blue). Dendrograms illustrate the clustering of cell lines and conditions based on viability response. (<bold>Lower panel</bold>) Example of the cytopathic effect of reovirus, Moscow strain, inactivated by UV irradiation or heating on Mel Mtp melanoma cells.</p></caption><graphic xlink:href="viruses-16-01944-g002" position="float"/></fig><fig position="float" id="viruses-16-01944-f003"><label>Figure 3</label><caption><p>The viability of hTERT-BJ fibroblast cells, human kidney epithelial NKE cells, and A549 lung carcinoma cells incubated with reovirus, Moscow strain, at different MOIs. The X-axis represents time post infection (hours), and the Y-axis shows cell viability (%). The cell viability corresponds to the optical density values for the infected cell culture, expressed as a percentage of the values for a similar uninfected culture immediately before infection (0 h).</p></caption><graphic xlink:href="viruses-16-01944-g003" position="float"/></fig><fig position="float" id="viruses-16-01944-f004"><label>Figure 4</label><caption><p>The production levels of phosphorylated PKR in melanoma cell lines, primary glioblastoma cells, and resistant cells: the lung carcinoma cell line, A549, and non-malignant cells, NKE and hTERT-BJ, were assessed analyzed by ELISA. Cell lines were ranged by <italic toggle="yes">p</italic>-values. Each bar represents the mean PKR levels, with error bars indicating the standard deviation (SD). Dark gray bars (K) indicate uninfected cells, whereas light gray bars (Reo) represent reovirus-infected cells. * <italic toggle="yes">p</italic> &#x0003c; 0.05; *** <italic toggle="yes">p</italic> &#x0003c; 0.001; ns&#x02014;not significant.</p></caption><graphic xlink:href="viruses-16-01944-g004" position="float"/></fig><fig position="float" id="viruses-16-01944-f005"><label>Figure 5</label><caption><p><italic toggle="yes">EGFR</italic> gene (gene ID&#x02014;ENSG00000146648) expression in glioblastoma cells as measured by mRNA sequencing. Each bar represents mean log fold change, with error bars indicating standard deviation (SD). FC indicates fold change.</p></caption><graphic xlink:href="viruses-16-01944-g005" position="float"/></fig><fig position="float" id="viruses-16-01944-f006"><label>Figure 6</label><caption><p>Accumulation of RNA from replication-competent and inactivated (via heating (heat) and UV irradiation (UV)) reovirus intracellularly after infecting melanoma cell lines and primary glioblastoma cells with MOI of 0.1. The X-axis represents the time post inoculation, while the Y-axis indicates the RNA accumulation expressed in log<sub>10</sub>TCID<sub>50</sub>/mL. * indicates <italic toggle="yes">p</italic>-value between RNA accumulation in cells infected with reovirus and infected in the presence of a cathepsin inhibitor.</p></caption><graphic xlink:href="viruses-16-01944-g006a" position="float"/><graphic xlink:href="viruses-16-01944-g006b" position="float"/></fig><fig position="float" id="viruses-16-01944-f007"><label>Figure 7</label><caption><p>The expression level of the cathepsin S gene mRNA in infected and uninfected glioblastoma cell lines. Cells were infected with the virus at a multiplicity of infection (MOI) of 1.0, and the mRNA levels were assessed at the specified time points using real-time quantitative PCR (qRT-PCR).</p></caption><graphic xlink:href="viruses-16-01944-g007" position="float"/></fig><fig position="float" id="viruses-16-01944-f008"><label>Figure 8</label><caption><p>Toxic effect of cathepsin inhibitors on melanoma cells. The toxicity of cathepsin inhibitors was evaluated based on the percentage of viable Mel Il melanoma cells 24 h post incubation with inhibitors of cathepsins B and L.</p></caption><graphic xlink:href="viruses-16-01944-g008" position="float"/></fig><fig position="float" id="viruses-16-01944-f009"><label>Figure 9</label><caption><p>Modulation of cathepsin activity in reovirus-infected melanoma (<bold>upper panel</bold>) and glioblastoma (<bold>lower panel</bold>) cells. The cathepsin-mediated activity was assessed by the percentage of viable melanoma or glioblastoma cells at 24 h post incubation with reovirus at MOIs of 0.1, 1.0, and 10 in the presence of cathepsin inhibitor at concentrations of 5 and 10 mM and without cathepsin inhibitor (0 mM). Black boxes indicate significant differences.</p></caption><graphic xlink:href="viruses-16-01944-g009a" position="float"/><graphic xlink:href="viruses-16-01944-g009b" position="float"/></fig><fig position="float" id="viruses-16-01944-f010"><label>Figure 10</label><caption><p>Assessment of the viability of reovirus-infected and uninfected cell cultures following incubation with protease inhibitors. ProInh&#x02014;a protease inhibitor cocktail; CatInh&#x02014;an inhibitor of cathepsins B and L; Reo&#x02014;reovirus.</p></caption><graphic xlink:href="viruses-16-01944-g010" position="float"/></fig><fig position="float" id="viruses-16-01944-f011"><label>Figure 11</label><caption><p>Evaluation of the activity levels of cathepsins B, L, and S in cultures of human melanoma and glioblastoma cells, as well as in resistant cell lines (K): lung carcinoma cells, A549, non-tumorous fibroblasts, hTERT-BJ, and non-tumorous kidney epithelial cells, NKE, in supernatants (s/n) and cell lysates (lys). ** <italic toggle="yes">p</italic> &#x02264; 0.0057.</p></caption><graphic xlink:href="viruses-16-01944-g011a" position="float"/><graphic xlink:href="viruses-16-01944-g011b" position="float"/></fig><fig position="float" id="viruses-16-01944-f012"><label>Figure 12</label><caption><p>Luminescence analysis of caspases-3 and -7 activity levels in infected melanoma (Mel Mtp, Ibr, Il, and Z) and glioblastoma (Gbl13n, Gbl16n, Gbl25n, and Gbl27n) cells (48 h post infection). * <italic toggle="yes">p</italic> &#x0003c; 0.05; ** <italic toggle="yes">p</italic> &#x0003c; 0.01; *** <italic toggle="yes">p</italic> &#x0003c; 0.001.</p></caption><graphic xlink:href="viruses-16-01944-g012" position="float"/></fig><fig position="float" id="viruses-16-01944-f013"><label>Figure 13</label><caption><p>Cytometric analysis of apoptosis in (<bold>a</bold>) Mel Ibr; (<bold>b</bold>) Mel Mtp; (<bold>c</bold>) Mel Z; and (<bold>d</bold>) Mel Il cells. Mock (or K)&#x02014;uninfected cells; Reo&#x02014;cells infected with reovirus (24 h.p.i.); Reo+CI&#x02014;cells pretreated with a cathepsin inhibitor and infected with reovirus (24 h.p.i.); UV&#x02014;cells incubated with UV-inactivated reovirus (24 h.p.i.). All cells were stained with Annexin V/PI. OX&#x02014;FITC; OY&#x02014;PI. * <italic toggle="yes">p</italic> &#x0003c; 0.05.</p></caption><graphic xlink:href="viruses-16-01944-g013a" position="float"/><graphic xlink:href="viruses-16-01944-g013b" position="float"/></fig><table-wrap position="float" id="viruses-16-01944-t001"><object-id pub-id-type="pii">viruses-16-01944-t001_Table 1</object-id><label>Table 1</label><caption><p>ED<sub>50</sub> for melanoma cell lines, primary glioblastoma cells, A549 and non-malignant cells.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Mel Il</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Mel Mtp</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Mel Ibr</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Gbl27n</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Gbl13n</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Gbl25n</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Mel Z</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Gbl16n</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Gbl24n</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">A549</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">NKE</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Gbl17n</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">hTERT-BJ</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Reovirus</td><td align="center" valign="middle" style="background:#FCE4D6" rowspan="1" colspan="1">0.67</td><td align="center" valign="middle" style="background:#FCE4D6" rowspan="1" colspan="1">1.06</td><td align="center" valign="middle" style="background:#F8CBAD" rowspan="1" colspan="1">2.74</td><td align="center" valign="middle" style="background:#F8CBAD" rowspan="1" colspan="1">2.74</td><td align="center" valign="middle" style="background:#F8CBAD" rowspan="1" colspan="1">2.86</td><td align="center" valign="middle" style="background:#F4B084" rowspan="1" colspan="1">3.09</td><td align="center" valign="middle" style="background:#F4B084" rowspan="1" colspan="1">3.14</td><td align="center" valign="middle" style="background:#F4B084" rowspan="1" colspan="1">3.79</td><td align="center" valign="middle" style="background:#ED7D31" rowspan="1" colspan="1">4.33</td><td align="center" valign="middle" style="background:#ED7D31" rowspan="1" colspan="1">4.83</td><td align="center" valign="middle" style="background:#C65911" rowspan="1" colspan="1">6.43</td><td align="center" valign="middle" style="background:#C65911" rowspan="1" colspan="1">6.49</td><td align="center" valign="middle" style="background:#C65911" rowspan="1" colspan="1">6.84</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">UV-inactivated</td><td align="center" valign="middle" style="background:#BDD7EE" rowspan="1" colspan="1">5.20</td><td align="center" valign="middle" style="background:#DDEBF7" rowspan="1" colspan="1">4.19</td><td align="center" valign="middle" style="background:#BDD7EE" rowspan="1" colspan="1">4.99</td><td align="center" valign="middle" style="background:#BDD7EE" rowspan="1" colspan="1">5.88</td><td align="center" valign="middle" style="background:#9BC2E6" rowspan="1" colspan="1">6.03</td><td align="center" valign="middle" style="background:#9BC2E6" rowspan="1" colspan="1">6.19</td><td align="center" valign="middle" style="background:#DDEBF7" rowspan="1" colspan="1">4.19</td><td align="center" valign="middle" style="background:#9BC2E6" rowspan="1" colspan="1">6.37</td><td align="center" valign="middle" style="background:#9BC2E6" rowspan="1" colspan="1">6.45</td><td align="center" valign="middle" style="background:#2F75B5" rowspan="1" colspan="1">6.85</td><td align="center" valign="middle" style="background:#1F4E78" rowspan="1" colspan="1">n/a</td><td align="center" valign="middle" style="background:#2F75B5" rowspan="1" colspan="1">6.93</td><td align="center" valign="middle" style="background:#1F4E78" rowspan="1" colspan="1">n/a</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">heat-inactivated</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#C6E0B4" rowspan="1" colspan="1">6.48</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#E2EFDA" rowspan="1" colspan="1">6.18</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#C6E0B4" rowspan="1" colspan="1">6.80</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#C6E0B4" rowspan="1" colspan="1">8.42</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#C6E0B4" rowspan="1" colspan="1">6.70</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#A9D08E" rowspan="1" colspan="1">7.10</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#E2EFDA" rowspan="1" colspan="1">6.18</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#A9D08E" rowspan="1" colspan="1">7.85</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#A9D08E" rowspan="1" colspan="1">7.54</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#548235" rowspan="1" colspan="1">8.00</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#375623" rowspan="1" colspan="1">n/a</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#548235" rowspan="1" colspan="1">9.21</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#375623" rowspan="1" colspan="1">n/a</td></tr></tbody></table><table-wrap-foot><fn><p>Colors vary from pale to a bright shade with increasing resistance to reovirus-mediated oncolysis.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="viruses-16-01944-t002"><object-id pub-id-type="pii">viruses-16-01944-t002_Table 2</object-id><label>Table 2</label><caption><p>Cathepsin expression levels in uninfected glioblastoma cells.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Name</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">LogCPM Rank (%)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Gbl13n</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Gbl16n</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Gbl17n</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Gbl24n</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Gbl25n</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Gbl27n</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">cathepsin A </td><td align="center" valign="middle" rowspan="1" colspan="1">93.9</td><td align="center" valign="middle" style="background:#DBBEA2" rowspan="1" colspan="1">383.5</td><td align="center" valign="middle" style="background:#D4C5B7" rowspan="1" colspan="1">262.0</td><td align="center" valign="middle" style="background:#D8C1AB" rowspan="1" colspan="1">327.8</td><td align="center" valign="middle" style="background:#CBCCCF" rowspan="1" colspan="1">166.9</td><td align="center" valign="middle" style="background:#C8CBD0" rowspan="1" colspan="1">157.4</td><td align="center" valign="middle" style="background:#BAC3D7" rowspan="1" colspan="1">117.2</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">cathepsin B </td><td align="center" valign="middle" rowspan="1" colspan="1">99.4</td><td align="center" valign="middle" style="background:#C65911" rowspan="1" colspan="1">1348.7</td><td align="center" valign="middle" style="background:#833C0C" rowspan="1" colspan="1">2146.8</td><td align="center" valign="middle" style="background:#989CA4" rowspan="1" colspan="1">873.2</td><td align="center" valign="middle" style="background:#8F98AB" rowspan="1" colspan="1">764.8</td><td align="center" valign="middle" style="background:#CAAE93" rowspan="1" colspan="1">1068.7</td><td align="center" valign="middle" style="background:#AE957C" rowspan="1" colspan="1">1454.0</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">cathepsin C </td><td align="center" valign="middle" rowspan="1" colspan="1">83.5</td><td align="center" valign="middle" style="background:#EBD1B9" rowspan="1" colspan="1">206.5</td><td align="center" valign="middle" style="background:#E6DBD0" rowspan="1" colspan="1">119.8</td><td align="center" valign="middle" style="background:#D8DDE5" rowspan="1" colspan="1">60.2</td><td align="center" valign="middle" style="background:#D5DBE6" rowspan="1" colspan="1">55.3</td><td align="center" valign="middle" style="background:#E7D8C9" rowspan="1" colspan="1">138.8</td><td align="center" valign="middle" style="background:#E4DED8" rowspan="1" colspan="1">98.7</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">cathepsin D </td><td align="center" valign="middle" rowspan="1" colspan="1">96.8</td><td align="center" valign="middle" style="background:#CAAE93" rowspan="1" colspan="1">394.5</td><td align="center" valign="middle" style="background:#CAAD90" rowspan="1" colspan="1">410.1</td><td align="center" valign="middle" style="background:#ED7D31" rowspan="1" colspan="1">1078.4</td><td align="center" valign="middle" style="background:#A6B1C6" rowspan="1" colspan="1">152.4</td><td align="center" valign="middle" style="background:#C5B29E" rowspan="1" colspan="1">331.1</td><td align="center" valign="middle" style="background:#809EDC" rowspan="1" colspan="1">78.1</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">cathepsin K </td><td align="center" valign="middle" rowspan="1" colspan="1">85.8</td><td align="center" valign="middle" style="background:#9BC2E6" rowspan="1" colspan="1">6.1</td><td align="center" valign="middle" style="background:#D4D9E3" rowspan="1" colspan="1">28.3</td><td align="center" valign="middle" style="background:#D5D9E3" rowspan="1" colspan="1">29.0</td><td align="center" valign="middle" style="background:#E7D1BD" rowspan="1" colspan="1">84.2</td><td align="center" valign="middle" style="background:#A4BEF4" rowspan="1" colspan="1">8.1</td><td align="center" valign="middle" style="background:#D6DAE2" rowspan="1" colspan="1">30.1</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">cathepsin L </td><td align="center" valign="middle" rowspan="1" colspan="1">94.3</td><td align="center" valign="middle" style="background:#D5C2AF" rowspan="1" colspan="1">283.0</td><td align="center" valign="middle" style="background:#D9BDA2" rowspan="1" colspan="1">361.8</td><td align="center" valign="middle" style="background:#BFC6D3" rowspan="1" colspan="1">129.6</td><td align="center" valign="middle" style="background:#C5C9CF" rowspan="1" colspan="1">147.1</td><td align="center" valign="middle" style="background:#B5C0D7" rowspan="1" colspan="1">106.2</td><td align="center" valign="middle" style="background:#9DB4E3" rowspan="1" colspan="1">64.7</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">cathepsin S </td><td align="center" valign="middle" rowspan="1" colspan="1">91.6</td><td align="center" valign="middle" style="background:#BBC7E0" rowspan="1" colspan="1">33.1</td><td align="center" valign="middle" style="background:#B3C3E3" rowspan="1" colspan="1">27.5</td><td align="center" valign="middle" style="background:#8BAEF5" rowspan="1" colspan="1">11.1</td><td align="center" valign="middle" style="background:#87ACF7" rowspan="1" colspan="1">3.4</td><td align="center" valign="middle" style="background:#BEC9DF" rowspan="1" colspan="1">35.3</td><td align="center" valign="middle" style="background:#87ACF7" rowspan="1" colspan="1">1.4</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">cathepsin Z </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">87.8</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#DADBDD" rowspan="1" colspan="1">96.6</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#D0D6E1" rowspan="1" colspan="1">75.8</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#CAD2E3" rowspan="1" colspan="1">65.0</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#DDDBD9" rowspan="1" colspan="1">107.6</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#DFD9D3" rowspan="1" colspan="1">125.1</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#E7CCB1" rowspan="1" colspan="1">258.0</td></tr></tbody></table><table-wrap-foot><fn><p>CPM&#x02014;counts per million reads. Numbers represent logFC (fold change) for each cell line. A blue-to-red color heatmap illustrates per-sample gene expression profiles normalized to the average value (geometric mean) across all samples, per each gene.</p></fn></table-wrap-foot></table-wrap></floats-group></article>